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STUDIES ON SOME HETEROCYCLIC COMPOUNDS IN MEDICINAL
INTEREST
INTRODUCTION
Heterocyclic chemistry has been unparalled progress owing to their wide
natural occurance, specific chemical reactivity and broad spectrum utility.
Hetrocyclic compounds have great applicability in pharmaceutical, because
they have specific chemical reactivity and provides false synthons in biosynthetic
process.
Some heterocyclic compounds must ideally have a broad spectrum of
activity with a rapid bactericidal action. We must always continue to search new
heterocyclic moleculer and identify its respective drugs activity. To take the care
for synthesis new heterocyclic moleculer a lower toxicity, a partial or total absence
of undesirable side effects, more neutritive value, improved stability, a decrease
in production cost and chek the qualitative or quantitative improvement in activity
with standard drugs. Phenothiazine derivatives have been reported as a valuable
medicine in the treatment anthelmintic, antihistamine activity and also used in
the treatment of parkinson's disease. 4-(3H)-Quinazolones substituents serves as
nucleus to a host of compound which are associated with wide spectrum of
therapeutic activity cetrizine, chlorcyclizine, buclizine, cinnarizine,
chlorbenzoxamine and other piperazine derivatives showed a good antialergic
antihistaminic, hypochlolesterolenic, vasodilating and antiinflammatory activity.
Heterocyclic compound have great biological significance properties.
(1) They have a specific chemical reactivity.
(2) They resemble essential metabolism and can also provide false synthons in
biosynthetic process.
(3) They fit receptors and block their normal working.
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(4) They provide convenient buiding blockers to which biologically active
substituents can be attached.
The interesting biological activities of heterocycles have stimulated
considerable research work in recent years including to the synthetic utillity.
Heterocyclic compounds can be synthesised by cyclization reactions
(accompanied by elemination of small molecules) addition reactions (adduct
formation), ring transformation reactions or replacement involving groups.
Formation of heterocycle from acylic compounds alters the reactivity. Piperidine
is reactive than ethyl propylamine due to the reduction in steric incubrance of
the nitrogen lone pair.
AIMS AND OBJECTIVITS :
Poupulation of our country is skyrockating number of diseases are uncoured
eg. cancer, Aids etc.
In the pharmaceutical field, There is a need for new and novel chemical
inhibitors of biological functions. Our efforts are focused on the introduction of
chemical diversity in the molecular frame work in order to synthesising
pharmacologically interesting heterocyclic compounds of widely different
composition.
During the course of research work looking to the  applications of
heterocyclic compounds, several entities, have been designed, generated and
characterised using spectral studies. The aims and objectives of the work carried
out are as under.
(1) To synthesise pharmacologically active entities l ike Mannich bases,
sulphonamides,  ary lamide,  imidazol inones,  chalcones,  i soxazole,
pyrazolines, pyrimidines bearing 7-methyl phenothiazine-1-carboxylic acid,
7-methoxy phenothiazine-1-caroboxylic acid, [(4'-chlorophenyl) (phenyl)
methyl] piperazine, 2-[1'-(4"-chlorophenyl)-2'-methyl propyl]-3-amino
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quinazolin-4-(3H)-one, 3-amino-2-phenyl quinazolin-4-(3H)-one, 3-[4'-
acetyl phenyl]-2-phenyl quinazolin-4-(3H)-one nucleus.
(2) To characterise these products for structural elucidation using spectroscopic
technique like IR, NMR and Mass spectral studies.
(3) To check the purity of all compounds using thin layer chromatography.
(4) To evalute these new products for better drug potential against different strain
of bacteria and fungi activity.
The research work is presented as studies on [A] Phenothiazine [B]
Piperazine [C] Quinazoline 4-(3H)-one synthesis.
In a programmed research directed towards.  The construct ion of
therapeutically active new heterocycles bearing phenothiazine, piperazine,
quinazoline 4-(3H)-one nucleus has been investigated in following parts.
PART-I : STUDIES ON MANNICH BASES.
PART-II : STUDIES ON SULPHONAMIDES.
PART-III : STUDIES ON ARYLAMIDES.
PART-IV : STUDIES ON IMIDAZOLINONES.
PART-V : STUDIES ON CHALCONES.
PART-VI : STUDIES ON ISOXAZOLES.
PART-VII : STUDIES ON PYRAZOLINES.





STUDIES ON MANNICH BASES
INTRODUCTION
Mannich reaction consist of the condensation of ammonia or a primary or
secondary amine, usually as the hydrochloride, with formaldehyde (or some time
another aldehyde) and a compound containing atleast one hydrogen atom of
pronounced reactivity. The essential feature of the reaction is the replacement of
the active hydrogen atom by an aminomethyl or substituted aminomethyl group.
The product formed is referred to as Mannich base. Among these are the following
types with active hydrogen under lined.
Over the years there has been much controversy about the mechanism of
the Mannich reaction, especially as to whether the aldehyde is first attacked by
active hydrogen compound or by ammonia or amine. Studies of the reaction
kinetics have led to the following mechanistic proposals.
The Base-Catalysed Reaction :




– CH – CN – CH – NO2 – RC     CH




H2N – CH2 – CH2 – C – R
H – C – H  +  CH2 – C – R'
O







H – C – H
N.R2





The Acid-catalysed Reaction :
THE DIFFERENT METHODS FOR SYNTHESIS OF MANNICH BASES
ARE AS FOLLOWS.
(i) By the condensation of saturated ketones/cycloalkanones / α,β-unsaturated
ketones /  he terocyc l i c  ke tones  conta in ing a  carbony l  group wi th
formaldehyde and primary/secondary amines salts1-8.
(ii) By the reaction of α-hydrogen atom with substituted aliphatic/aromatic
aldehydes and primary/secondary amines salts9.
(iii) By the reaction of α-hydrogen atom of an acid/esters with formaldehyde
and primary/secondary aryl amines salts10,11.
(iv) By the reaction of substituted phenols with formaldehyde and primary/
secondary amines salts12-16.
(v) By the reaction of substituted phenyl acetylenes with formaldehyde and
primary/secondary amines salts17.
(vi) By the reaction of α-methyl group in a pyridine/quinoline nucleus with
formaldehyde and primary/secondary amines salts18,19.
Mannich bases showed a wide range of different types of therapeutic





H – C – H  + R2
.NH H – C – H
N.R2
OH



















Phenothiazine- (A) was known as thiodiphenylamine. When two benzene
nucleus are fused with 2,3 and 5,6 position of thiazine is called as phenothiazine.
the structure and numbering of phenothiazine is reported as below.
A. Bernthsen27 has synthesised phenothiazine by the reaction of diphenyl
amine and sulphur in the presence of catalytic amount of Iodine particles in 1883.
Phenothiazine (A) have been synthesised by the condensation of 2-chlorobenzoic
acid with aniline by Ullmann reaction28 in the presence of anhydrous K2CO3
and CuO. The most impor tant application of phenothiazines are as an
anthelmintics29,30 and insecticidal31 activities. Phenothiazine derivatives have














SYNTHESIS OF SUBSTITUTED PHENOTHIAZINES ARE AS FOLLOWS :
(i) By the action of diphenylamine with sulphur27.
(ii) By the action of diphenylamine with thionyl chloride29,30.
(iii) By the action of 2-aminothiophenol with 2,4,6-trinitrochlorobenzene in
presence of sodium hydroxide solution31.
(iv) By the action of 2-aminothiophenol with 2,5-dinitrochlorobenzene in
presence of sodium acetate solution33.
(v) By the action of 2-amino-2'-iodo-4',4'-dinitrodiphenyl sulphide in presence
of cupprous Iodide and sodium carbonate33.
(vi) By the action of phenothiazine in gla. acetic acid with sodium nitrite34.
(vii) By the action of 3-nitrophenothiazine in gla. aceticacid with hydrogen
chloride35.
(viii) By the action of 3,7-dinitrophenothiazine in dil. HCl with Sn/Zn metal36.
(ix) Synthesis of phenothiazine via smiles rearrangement37.
(x) practically synthesised 3,7-diIodo phenothiazine38.
V. H. Shah et. al. have been synthesised 10-N-arylamino methyl 1,3,7,9-
tetrachloro/H-phenotriazones39.
General structure of phenothiazine derivatives (B) are as under.

















Phenothiazine derivatives showed a wide range of different types of





















With a view of getting better therapeutic agents it was contemplated to
synthesis Mannich bases which have been described as under.
Section - I : Synthesis  and biological  screening of  10-N-
{[(Aryl)amino]methyl}-7-methyl phenothiazine-1-
carboxylic acid.





SYNTHESIS AND BIOLOGICAL SCREENING OF 10-N-{[(ARYL)
AMINO]METHYL}-7-METHYLPHENOTHIAZINE-1-CARBOXYLIC ACID.
In view of getting better therapeutic agents, the synthesis of 10-N{[(aryl)
amino]methyl}7-methyl phenothiazine-1-carboxilic acid of type - (I) have been
under taken by the interaction of aromatic amines, formaldehyde and 7-methyl
phenothiazine-1-carboxilic acid in presence of dil. hydrochloric acid [Mannich
reaction].
The constitution of the products were supported by elemental analyses IR,
NMR and Mass spectral data. The products were screened for antimicrobial activity
at a concentration of 50 µg. The details have been cited as under.







IR SPECTRAL STUDY OF 10-N-{[(4'-METHOXYPHENYL)AMINO]METHYL}-7-METHYL-
10-H-PHENOTHIAZINE-1-CARBOXYLIC ACID
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C–H str.(asym) 2920 2975-2950 110,111,112
C–H str. (sym) 2852 2890-2850 "
C–H def. (bending) 1452 1470-1435 "
Aromatic C–H str. 3065 3080-3030 110,111, 112
C–H Ring Skeletal 1452,1512 1600–1650 "
C–H i. p. def. 1253 1300-1100 "
C-H o.o.p. def. 752,661,806 832-750 "
C–S–C str. 617 700-600 112
C–N str. 1384 1380-1332 114
Amine N–H str. 3321 3550-3350 112
N–H def. 1606 1650-1550 "
-OCH
3
C–O–C 1218 1260-1220 109









NMR SPECTRAL STUDY OF 10–N–{[(4'-METHOXYPHENYL)AMINO]METHYL}–7–
METHYL–PEHNOTHIAZINE–1–CARBOXYLIC ACID.
Internal Standard : TMS; Solvent : CDCl3   : Instrument : BRUKER Spectrometer (200 MHz)
Signal Signal Position Relative No. Multiplicity Inference
No. (δ ppm) of Protons
1 2.20 3H singlet Ar-CH
3
2 3.7 3H singlet Ar-OCH
3
3 3.4 1H singlet NH-
4 7.2 1H doublet Ar-Ha
5 7.5 1H doublet Ar-Hb
6 7.9 1H singlet Ar-Hc
7 8.05-8.43 3H singlet Ar-Hd
8 8.6 2H doublet Ar-Hee'
9 8.9 2H doublet Ar-Hff'
10 2.3 2H singlet N-CH
2



























































































































.C6H4–(24) – – 4–Br
.C6H4–(20)
4–OH.C6H4–(24) 3–CH
.C6H4–(20) – – –
– 4–OCH3
.C6H4–(22) – – –
– 4–F.C6H4–(20) – – –
Comparable activity with known standard drugs :-
Ampicillin 22 18 19 27 –
Chloramphenicol 24 19 25 26 –
Norfloxacin 24 19 25 26 –
Griseofulvin – – – – 23
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
Antimicrobial activity :
Conclusion :
Maximum antimicrobial activity :
2
8
B. mega B. subtilis E. coli P. vulgaris A. niger
R R R R R
Reaction Scheme


























SYNTHESIS OF 10-N-ARYL AMINOMETHYL-7-METHYL
PHENOTHIAZINE-1-CARBOXYLIC ACID.
(A) Synthesis of 2-Carboxy-4'-methyl diphenyl amine.
A mixture of 2-chloro benzoicacid (1.56g, 0.01M) 4-methyl aniline (1.07g,
0.01M) were condensed in the presence of CuO and anhydrous K2CO3 by
Ullmann reaction. Yield : 98% ; mp. 120oC.
(B) Synthesis of 7-Methyl phenothiazine-1-carboxylic acid
A mixture of 2-carboxy-4'-methyl diphenyl amine (2.25g, 0.01M) and
sulphur (0.64g, 0.02M) were condensed in the presence of Iodine as a catalyst.
The product is cooled and poured into crushed ice. filtered, dried and recrystalised
from dioxane yield : 94%; m.p. 110oC (Found : C, 65.30; H, 4.20; N, 5.42;
C14H11O2NS requires : C : 65.36; H: 4.28; N: 5.44%)
(C) Synthesis of 10-N-{[(4'-Methoxy phenyl)amino]methyl}-7-methyl
phenothiazine-1-carboxylic acid.
A mixture of 7-methyl phenothiazine 1-carboxylic acid. (2.57g, 0.01M)
formaldehyde (2.0 ml), 4-methoxy aniline (1.23g, 0.01M) hydrochloric acid (5.0
ml) and dioxane (25 ml) was refluxed for 5 hrs on oil bath. The cold reaction
mixture was filtered and poured into crushed ice. The isolated products was
crystallised from dioxane yield : 76.62% m.p. 102oC, (Found : C, 67.30 ; H,
5.08; N,7.12; C22H20O3N2S required C : 67.34; H: 5.10; N : 7.14%).
 Similarly other Mannich bases have been synthesised and their physical
constant are recorded in Table No. 1.
(D) Antimicrobial activity of 10-N-Aryl amino methyl-7-methyl
phenothiazine-1-carboxylic acid.
The products were screened for antimicrobial activity at a concentration of
50µg. The details are as under.
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ANTIMICROBIAL ACTIVITY
Products : 7-methyl phenothiazine-1-carboxylic acid
Method : Cup-plate8
Gram positive bacteria : Bacillus megaterium
Bacillus subtillis
Gram negative bacteria : Escherichia coli
Pseudonomus vulgaris
Fungi : Aspergillus niger
Concentration : 50 µg.
Solvent : Dimethyl formamide
Standard drug : Ampicillin, Chloramphenicol, Norfloxacin,
Greseofulvin
The antibacterial activity was compared with standard drugs viz. ampicillin,
chloramphenicol, norfloxacin and antifungal activity was compared with standard
drugs viz griseofulvin. The zones of  inhibition were measured in mm. The zones
of inhibition that displayed by standard drugs are recorded in Part-1 Page no. 34
31
(E) Antimicrobial activity of 7-Methyl-phenothiazine-1-carboxilic acid
Method : It was carried out using the cup-plate method which has been
described as under.
Antibacterial activity107
The purified products were screened for their antibecterial activity. The
neutrient agarbroth prepared by the usual method, was inoculated specially with
0.5 ml for 24 hrs. Old subculture of Bacillus Megaterium, Bacillus subtillis,
Escherichia coli, Pseudonomus vulgaris in separate conical flasks at 40-
50oC and mixed well by gentle shaking. About 25ml of the contents of the flask
were poured and evenly spread in a petridish (13 cm in diameter) and allowed
to set for 2 hrs. The cups (10 mm in diameter) were formed by the help of borer
in a agar medium and filled with 0.10ml (1.0 mg/ml) solution of sample in
dimethyl formamide.
The plates were incubated at 35oC for 24 hrs. and the control was also
maintained with 0.1 ml of dimethyl formamide in similar manner and the zone of
inhibition of the bacterial growth are measured in mm diameter and are recorded
in Table No. A.
Antifungal activity108
Aspergillus niger was employed for testing fungicidal activity using cup-
plate method. The cultures ware maintained on subouraud's agar slants. Purified
compounds were used for testing the fungicidal activity. Sterlised sabouraud's
agar medium was inoculated with 72 hrs. Old 0.5 ml suspension of fungal spores
in a sterilised separate flask. About 25 ml of the inoculated medium was evently
spreaded in a petridish and allowed to set for 2 hrs. The cups (10 mm in a
diameter) were panched in petridish and loaded with 0.1 ml (1.0 mg/ml) of
solution of a sample in dimethyl formamide.
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The plate were incubated at room temperature 30oC for 48 hrs. After the
completion of incubation period. The zone of inhibition of growth in the form of
diameter in mm was measured. Along the test solution in each petridish one cup
was fillled up with solvent which acts as control. The zones of inhibition are
recorded in Table No. A.
33
TABLE NO. A : ANTIMICROBIAL ACTIVITY ZONE OF INHIBITION FOR STANDARD DRUGS.
1 Ampicillin (50µg) 22 18 19 27 –
2 Chloramphenicol (50µg) 24 19 25 26 –
3 Norfloxacin (50µg) 24 19 25 26 –
4 Griseofulvin (50µg) – – – – 23
B. mega B. subtillis E. coli P. vulgaris A. niger
Antibacterial activity
Zone of inhibition in m.m.
Antifungal activity



















1 C6H5– C21H18O2N2S 85 78.16 7.73 7.69
2 2–Cl.C6H4– C21H17O2N2SCl 70 85.22 7.06 7.01
3 3–Cl.C6H4– C21H17O2N2SCl 126 62.85 7.06 6.99
4 4–Cl.C6H4– C21H17O2N2SCl 76 58.98 7.06 7.03
5 2–NO2
.C6H4– C21H17O4N3S 212 80.49 10.31 10.25
6 3–NO2
.C6H4– C21H17O4N3S 150 75.52 10.31 10.12
7 4–NO2
.C6H4– C21H17O4N3S 160(d) 76.92 10.31 10.10
8 4–Br.C6H4– C21H17O2N2SBr 90 60.88 6.34 6.32
9 2–CH3
.C6H4– C22H20O2N2S 94 70.42 7.44 7.21
10 3–CH3
.C6H4– C22H20O2N2S 105 72.20 7.44 7.40
11 4–CH3
.C6H4– C22H20O2N2S 136 82.48 7.44 7.35
12 2–OCH3
.C6H4– C22H20O3N2S 72 62.87 7.14 7.10
13 3–OCH3
.C6H4– C22H20O3N2S 86 66.44 7.14 7.09
14 4–OCH3
.C6H4– C22H20O3N2S 102 76.62 7.14 7.12
15 4–F.C6H4– C21H17O2N2SF 92 75.82 7.36 7.35
16 2–OH.C6H4– C21H18O3N2S 210 50.98 7.40 7.31
17 3–OH.C6H4– C21H18O3N2S 204 60.40 7.40 7.25









TABLE NO. 2 : ANTIMICROBIAL ACTIVITY OF 10-N-{[(ARYL)AMINO]METHYL}-7-METHYL PHENOTHIAZINE-
1-CARBOXYLIC ACID.
Sr. No. R B. mega B. subtilis E. coli P. vulgaris A. niger
1 2 3 4 5 6 7
1 C6H5– 14 15 16 10 19
2 2–Cl.C6H4– 10 21 20 10 12
3 3–Cl.C6H4– 10 18 12 11 12
4 4–Cl.C6H4– 18 20 15 12 16
5 2–NO2
.C6H4– 22 18 18 14 16
6 3–NO2
.C6H4– 10 10 10 09 18
7 4–NO2
.C6H4– 10 24 16 10 20
8 4–Br.C6H4– 16 14 10 10 20
9 2–CH3
.C6H4– 24 12 13 13 12
10 3–CH3
.C6H4– 12 20 15 10 12
11 4–CH3
.C6H4– 11 18 10 18 10
12 2–OCH3
.C6H4– 15 18 14 12 18
13 4–OCH3
.C6H4– 16 18 16 13 18
14 4–OCH3
.C6H4– 18 22 16 14 16
15 4–F.C6H4– 20 20 18 19 18
16 2–OH.C6H4– 10 15 14 10 18
17 3–OH.C6H4– 12 17 19 12 12
18 4–OH.C6H4– 24 13 12 11 14
Antibacterial activity
Zone of inhibition in m.m.
Antifungal activity




SYNTHESIS AND BIOLOGICAL SCREENING OF 10-N-{[(ARYL)
AMINO] METHYL}-7-METHOXY PHENOTHIAZINE-1-CARBOXYLIC
ACID.
Taking into consideration of wide ranging of therapeutic activity of
phenothiazine derivatives, the synthesis of 10-N-{[(aryl)amino]methyl}-7-
methoxy phenothiazine-1-carboxylic acid of Type-(II) have been undertaken by
the condensation of 7-methoxy phenothiazine-1-carboxilic acid with arylamine,
formaldehyde in presence of hydrochloric acid. The letter was 7-methoxy
phenothiazine-1-carboxylic acid was synthesised by chemoselective cyclization
of 2-carboxy 4'-methoxy diphenyl amine with sulphur in presence of Iodine. The
2-carboxy 4'-methoxy diphenyl amine have been synthesis by 2-chloro benzioc
acid with 4-methoxy aniline in presense of CuO and anhydrous K2CO3 (Ullmann
reaction)
The constitution of the products were supported by elemental analyses IR
and NMR spectral studies. The products were screened for antimicrobial activity
at a concentration of 50 mg. The details have been cited in Part-1, Section-1,
Page No.31-34.









IR SPECTRAL STUDY OF 10-N-{[(4'-METHYLPHENYL)AMINO]METHYL}-7-METHOXY-
PHENOTHIAZINE-1-CARBOXYLIC ACID.
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2920 2975–2950 110,111,112
C – H str. (sym) 2852 2890–2850 "
–CH3 C–H def. (asym) 1434 1470–1435 "
C – H bend 1458 1485–1440 "
Aromatic C–H str. 3060 3080–3030 111, 112
C=C Ring Skeletal 1508,1593 1600–1000 "
C–H o.o.p. def. 815,772,661 832–750 "
C–S–C str. 638 700–600 112
Amine N–H str. 3319 3550–3350 114
N–H def. 1593 1650–1550 "
–OCH3 C–O–C (asym) 1242 1260–1220 109
C–O–C (sym) 1033 1075–1020 "
–COOH >C=O, –COOH. str. 1662 1720–1650 "









NMR SPECTRAL STUDY OF 10-N-{[(4'-METHYLPHENYL)AMINO]METHYL}-7-
METHOXY-PHENOTHIAZINE-1-CARBOXYLIC ACID.
Internal Standard : TMS; Solvent : DMSO   : Instrument : BRUKER Spectrometer (200 MHz)
Signal Signal Position Relative No. Multiplicity Inference
No. (δ ppm) of Protons
1 2.51 3H singlet Ar–CH3
2 3.82 3H singlet Ar–OCH3
3 3.4 1H singlet –NH
4 8.75 1H doublet Ar–Ha
5 8.71 1H doublet Ar–Hb
6 7.8 1H singlet Ar–Hc
7 8.05–8.09 3H singlet Ar–Hd
8 7.0–7.5 2H doublet Ar–Hee'
9 6.9 2H doublet Ar–Hff'
10 2.7 2H singlet N–CH
2























































































































4–OH.C6H4–(23) – – 4–OH
.C6H4–(21) –
Comparable activity with known standard drugs :-
Ampicillin 22 18 19 27 –
Chloramphenicol 24 19 25 26 –
Norfloxacin 24 19 25 26 –
Griseofulvin – – – – 23
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
Antimicrobial activity :
Conclusion :
Maximum antimicrobial activity :
4
2
B. mega B. subtilis E. coli P. vulgaris A. niger
R R R R R



























SYNTHESIS OF 10-N-{[(ARYL) AMINO]METHYL}-7-METHOXY
PHENOTHIAZINE-1-CARBOXYLIC ACID.
(A) Synthesis of 2-Carboxy-4'-methoxy dipheyl amine.
A mixture of 2-chlorobenzoic acid (1.56g, 0.01M) 4-methoxyaniline (1.23g,
0.01M) were condensed in the presence of CuO and anhydrous K2CO3 by
Ullmann reaction (m.p. 120oC).
(B) Synthesis of 7-Methoxy-1-carboxy phenothiazine.
A mixture of 2-carboxy-4'-methoxy diphenyl amine (2.49g, 0.01M) and
sulphur (0.64g, 0.02M) were condensed in the presence of Iodine as a catalyst.The
product is cooled and poured into crushed ice. filtered, dried and recrystallised
from dioxane. Yield : 85.00% ; m.p. 90oC (Found : C, 61.56; H, 4.02; N, 5.11
C14H11O3NS required C, 61.53; H, 4.02; N, 5.12%).
(C) Synthesis of 10-N-{[(4'-Methylphenyl)amino]methyl}-7-methoxy
phenothiazine-1-carboxylic acid.
A mixture  of  7-methoxy-1-carboxyphenothiaz ine (2.73g,  0 .01M)
formaldehyde (2.0 ml) 4-methyl aniline (1.07 g, 0.01 M) hydrochloric acid (5.0
ml) and dioxan (25 ml) was refluxed for 5 hrs. on oil bath. The reaction mixture
was cooled and poured into crushed ice. The isolated product was crystallised
from dioxane; yield : 76.36%; m.p. 110oC (Found : C, 67.30; H, 5.08; N, 7.10;
C22H20O3N2S required C, 67.34; H, 5.10; N, 7.14%).
Similarly other compounds were synthesised and their physical constants
are recorded in Table No. 3.
(D) Antimicrobial activity of 10-N-{[(Aryl)amino]methyl}-7-methoxy
phenothiazine-1-carboxilic acid
The antimicrobial activity of the products were carried out as discribed in
Part-I, Section-I, Page No.31-34. The zone of inhibition of the test solutions are




















1 C6H5– C21H18O3N2S 152 70.68 7.40 7.38
2 2–Cl.C6H4– C21H17O3N2SCl 216 72.49 6.78 6.75
3 3–Cl.C6H4– C21H17O3N2SCl 201 70.20 6.78 6.74
4 4–Cl.C6H4– C21H17O3N2SCl 158 65.36 6.78 6.76
5 2–NO2
.C6H4– C21H17O5N3S 228 72.42 9.92 9.90
6 3–NO2
.C6H4– C21H17O5N3S 186 78.44 9.92 9.89
7 4–NO2
.C6H4– C21H17O5N3S 180 72.24 9.92 9.87
8 4–Br.C6H4– C21H17O3N2SBr 141 76.48 6.12 6.10
9 2–CH3
.C6H4– C22H20O3N2S 122 80.44 7.14 7.12
10 3–CH3
.C6H4– C22H20O3N2S 95 62.69 7.14 7.13
11 4–CH3
.C6H4– C22H20O3N2S 110 76.36 7.14 7.10
12 2–OCH3
.C6H4– C22H20O4N2S 118 58.28 6.86 6.84
13 4–OCH3
.C6H4– C22H20O4N2S 212 75.79 6.86 6.82
14 4–F.C6H4– C21H17O3N2S 134 84.42 7.07 7.06
15 2–OH.C6H4- C21H18O4N2S 220 55.65 7.10 7.06
16 3–OH.C6H4– C21H18O4N2S 255 65.92 7.10 7.08
17 4–OH.C6H4– C21H18O4N2S 226 78.46 7.10 7.09
18 2,3–(Cl)2






TABLE NO. 4 : ANTIMICROBIAL ACTIVITY OF 10-N-{[(ARYL)AMINO]METHYL}-7-METHOXY
PHENOTHIAZINE-1-CARBOXYLIC ACID.
1 C6H5– 14 18 16 22 12
2 2–Cl.C6H4– 12 17 12 18 15
3 3–Cl.C6H4– 14 21 18 17 17
4 4–Cl.C6H4– 15 19 20 16 19
5 2–NO2
.C6H4– 15 20 23 13 15
6 3–NO2
.C6H4– 17 21 18 15 18
7 4–NO2
.C6H4– 19 18 19 21 21
8 4–Br.C6H4– 22 20 23 19 20
9 2–CH3
.C6H4– 18 16 18 17 18
10 3–CH3
.C6H4– 20 14 17 19 17
11 4–CH3
.C6H4– 23 21 16 15 14
12 2–OCH3
.C6H4– 19 20 22 20 18
13 4–OCH3
.C6H4– 21 19 15 23 21
14 4–F.C6H4– 23 22 14 21 20
15 2–OH.C6H4– 17 16 15 14 16
16 3–OH.C6H4– 18 14 12 13 18
17 4–OH.C6H4– 23 15 18 21 20
18 2,3–(Cl)2
.C6H3– 19 13 16 18 19
Sr. No. R B. mega B. subtilis E. coli P. vulgaris A. niger
1 2 3 4 5 6 7
Antibacterial activity
Zone of inhibition in m.m.
Antifungal activity




SYNTHESIS AND BIOLOGICAL SCREENING OF 1-N-(ARYL AMINO
METHYL)-4-[(4'-CHLOROPHENYL) (PHENYL) METHYL]-PIPERAZINE.
[(4'-Chlorophenyl) (phenyl) methyl]-piperazine (C) and its derivatives gave
antihistamine activity. The number of structure is reported are as under.
C. De Vos et al. have been synthesised cetrizine (115) and reported its
antihistamine activity.











A. Antomio et. al. have been synthesised 1-[2-(2-thienyl)-methyl-4-[(4'-









































[     ]
[     ]
O. Hiroshi et al. have been synthesised the 1-benzyl-4-diphenyl methyl
piperazines and reported to a vasodilating activity.
John J. Piwinski et al. have been synthesised 1-(aroyl)-4-[(diphenyl)methyl]-
piperazine reported allergic inhibitors and antiinflammatory activity.







R = H, 4-OH,4-F,4-Cl,4-OAC etc.







R1 = R2 = R3 =H, halo, CF3 etc.
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[     ]
B. G. Robert et al. have been synthesised 1-(Aryl sulfonyl)-4-[(1-(4-pyridyl)
(piperidin-4-yl) carbonyl]-piperazines and analogs useful as oxido squalene
cyclase inhibirtors.131
R. H. Manzo et al. have been synthesised sulphonamido piperazine
derivatives and reported as a antibacterial properties.132
THERAPEUTIC IMPORTANCE :
Piperazine and [(4'-chlorophenyl) (phenyl) methyl]-piperazine derivatives
showed a wide range of differant types of therapeutic activities which are as follow.
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(f) Cardiovascular agent 139,143,144,146
(g) Vasodilating agent 141,145
(h) Antialergic 142
(i) Antiinflammatory 142
(j) Antimicrobial activity 151
(k) Anticoagulant agents 152
(l) Antiviral activity 153
(m) Antagonistic activity 154
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In view of getting better therapeutic agents. The synthesis of 1-N-[(aryl)
amino methyl]-4-[(4'-chlorophenyl) (phenyl) methyl]-piperazine of type (III) have
been synthesised by the condensation of [(4'-chlorophenyl) (phenyl) methyl]-
piperazine, formaldehyde, arylamine in presence of hydrochloric acid. [Mannich
reaction].
The constitution of the products were supported by elemental analyses IR,
NMR, Mass spectral studies. The products were screened for antimicrobial activity







Type - (III) R = Aryl
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IR SPECTRAL STUDY OF 1-N-[(2'3'-DICHLORO PHENYL)AMINOMETHYL]-4-[(4"-
CHLOROPHENYL (PHENYL)METHYL]-PIPERAZINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2922 2975–2950 110,111,112
C – H str. (sym) 2852 2890–2850 "
C – H bending 1465 1400–1500 "
Aromatic C–H str. 3050 3080–3030 111, 112
C–H Ring Skeletal 1460,1505 1600–1650 "
C–H i. p. def. 1274 1300–1100 "
C–H o.o.p. def. 800 832–802 "
C–N str. 1348 1380–1332 113
Amine N–H str. 3409 3550–3350 111,112
N–H def. 1600 1650–1550 "








NMR SPECTRAL STUDY OF 1-N-[(2'3'-DICHLORO PHENYL) AMINOMETHYL]-4-[(4"-
CHLOROPHENYL) (PHENYL)METHYL]-PIPERAZINE.
Internal Standard : TMS; Solvent : DMSO   : Instrument : BRUKER Spectrometer (200 MHz)
Signal Signal Position Relative No. Multiplicity Inference
No. (δ ppm) of Protons
1 6.5–7.2 5H singlet Ar–Ha
2 7.3 2H doublet Ar-Hbb'
3 7.59 2H doublet Ar–Hc
4 8.02 3H multiplet Ar–Hd,e,f
5 3.9 1H singlet NH–
6 2.9 2H singlet N–CH
7 2.75 8H singlet N–CH
2




















































































































Comparable activity with known standard drugs :-
Ampicillin 22 18 19 27 –
Chloramphenicol 24 19 25 26 –
Norfloxacin 24 19 25 26 –
Griseofulvin – – – – 23
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
Antimicrobial activity :
Conclusion :
Maximum antimicrobial activity :
5
7
B. mega B. subtilis E. coli P. vulgaris A. niger
R R R R R
























SYNTHESIS OF 1-N-(ARYL AMINOMETHYL)-4-[(4'-CHLOROPHENYL)
(PHENYL)METHYL]-PIPERAZINE.
(A) Synthesis of 4-Chlorobenzophenone :
A mixture of 4-chloro benzoyl chloride (1.75 g, 0.01 M) benzene (0.78 g,
0.01 M) were condensed in the presence of anhydrous AlCl3 by Fridalcraft's
reaction, yield: 86.00%, m.p. : 78oC.
(B) Synthesis of 1-(4'-Chloro phenyl) (phenyl) methanol.
A mixture of 4-chloro benzophenone (2.16 g, 0.01 M) sodium borohydrate
(1.0 gm) 1N NaOH Soln. (10 ml) and methanol (50 ml) reflux in 5 hrs. The
reaction mixture is cooled out at room temp. and poured into crushed ice,
nutralized with hydrochloric acid. The product so obtained was filtered and
washed with water dried crystalized with methanol, yield : 83.00%, mp: 44oC
(Found C; 71.36; H, 5.01; Cl, 16.23; C13H11OCl, required : C, 71.39 ; H, 5.03
; Cl, 16.24%).
(C) Synthesis of (4'Chlorophenyl) (phenyl) methyl chloride.
A mixture of 1-(4'-chloro phenyl) (phenyl) methanol (2.18 g, 0.01 M) thionyl
chloride (3.0 ml) benzene (20 ml) temp. mantain 25-30oC at 2 to 3 hrs then after
temp raised 75-80oC for 8 hrs refluxed it, benzene is distilled out. The reaction
mixture is cooled poured into crushed ice, wash with cold water, filtered, dried,
recrystalized from methanol. yield: 82.09%, m.p.: 122oC (Found : C ; 65.79 ; H,
4.18; Cl, 29.89, C13H10Cl2 required C, 65.82; H, 4.21; Cl, 29.95%).
(D) Synthesis of [(4'-Chloro phenyl) (phenyl) methyl]-piperazine :
A mixture of (4'-chloro phenyl) (phenyl) methyl chloride (2.37 g, 0.01 M)
anhydrous piperazine (2.88 g, 0.04 M) ethanol (20 ml) with triethanol amine
59
(5 ml) reflux for 4 hrs. The reaction mixture poured into ice cold water, filtered
and dried recrystalized from ethanol Yield : 84.00% m.p. : 74% (Found : C, 71.19;
H, 6.58, N, 9.76; C17H19N2Cl required : C, 71.20; H, 6.63; N, 9.77%).
(E) Synthesis of 1-N-[(2'-3'-Dichloro phenyl) amino methyl]-4-[(4"-
chlorophenyl) (phenyl) methyl]-piperazine.
A mixture of [(4'-chlorophenyl) (phenyl)methyl]piperazine (2.86 g, 0.01 M)
2,3 dichloro aniline (1.62 g, 0.01 M) formaldehyde (1.0ml) and hydrochloric
acid (5.0 ml) methanol (25 ml). The reaction mixture was refluxed on 3 hrs in
water bath. The cold reaction mixture was filtered and poured into crushed ice.
The isolated product was crystallised from methanol Yield : 83.93%, m.p. : 156oC
(Found : C, 62.48; H, 5.20; N, 9.10; C24H24N3Cl3 required : C, 62.54; H, 5.21;
N, 9.12%).
Similarly other Mannich bases were prepared. The physical constants are
recorded in Table No. 5.
(F) Antimicrobial activity of 1-N-(Arylamino methyl)-4-[(4'-chloro
phenyl) (phenyl) methyl]-piperazine.
The antimicrobial testing was carried out as described in Part-I, Section-I,
























1 C6H5– C24H26N3Cl 242 70.30 10.72 10.70
2 2–Cl.C6H4– C24H25N3Cl2 190 68.16 9.85 9.83
3 3–Cl.C6H4– C24H25N3Cl2 102 79.36 9.85 9.82
4 4–Cl.C6H4– C24H25N3Cl2 65 62.44 9.85 9.80
5 2–NO2
.C6H4– C24H25O2N4Cl 268 70.36 12.82 12.75
6 3–NO2
.C6H4– C24H25O2N4Cl 147 72.31 12.82 12.79
7 4–NO2
.C6H4– C24H25O2N4Cl 130 72.38 12.82 12.80
8 4–Br.C6H4– C24H25N3ClBr 80 57.62 8.92 8.90
9 2–CH3
.C6H4– C25H28N3Cl 129 74.30 10.35 10.27
10 3–CH3
.C6H4– C25H28N3Cl 134 70.49 10.35 10.31
11 4–CH3
.C6H4– C25H28N3Cl 140 72.32 10.35 10.33
12 2–OCH3
.C6H4– C25H28ON3Cl 80 70.20 9.96 9.95
13 4–OCH3
.C6H4– C25H28ON3Cl 108 70.38 9.96 9.90
14 4–F.C6H4– C24H25N3ClF 90 65.28 10.25 10.18
15 2–OH.C6H4- C24H26ON3Cl 195 79.24 10.30 10.17
16 3–OH.C6H4– C24H26ON3Cl 204 72.80 10.30 10.25
17 4–OH.C6H4– C24H26ON3Cl 193 73.62 10.30 10.29
18 2,3–(Cl)2
.C6H3– C24H24N3Cl3 156 83.93 9.12 9.10 61
TABLE NO. 6 : ANTIMICROBIAL ACTIVITY OF 1-N-{[(ARYL)AMINO]METHYL}-4-[(4'-CHLOROPHENYL)
(PHENYL) METHYL] PIPERAZINE.
1 C6H5– 18 16 19 21 16
2 2–Cl.C6H4– 20 18 16 17 18
3 3–Cl.C6H4– 19 17 18 20 19
4 4–Cl.C6H4– 23 22 20 21 20
5 2–NO2
.C6H4– 15 15 18 23 15
6 3–NO2
.C6H4– 17 18 17 18 17
7 4–NO2
.C6H4– 19 18 16 14 19
8 4–Br.C6H4– 18 18 15 21 22
9 2–CH3
.C6H4– 14 17 19 16 14
10 3–CH3
.C6H4– 15 14 17 17 17
11 4–CH3
.C6H4– 17 12 14 19 16
12 2–OCH3
.C6H4– 19 14 16 15 17
13 4–OCH3
.C6H4– 21 19 20 18 19
14 4–F.C6H4– 16 17 19 21 21
15 2–OH.C6H4– 18 19 20 20 17
16 3–OH.C6H4– 17 17 16 18 19
17 4–OH.C6H4– 18 16 18 23 23
18 2,3–(Cl)2
.C6H3– 20 16 17 24 23
Sr. No. R B. mega B. subtilis E. coli P. vulgaris A. niger
1 2 3 4 5 6 7
Antibacterial activity
Zone of inhibition in m.m.
Antifungal activity








The discovery of sulphonamides marked the begining of chemotherapeutic
era by making posible a direct attack on microbial infection155. Sulphonamide
antibacterials continue to be used because they are effective, inexpensive and
free of super infection problems of the broad spectrum antibiotics156.
Sulphonamide have the general formula of R-SO2-N-R'-R" where R=organic
radical R' and R"=Hydrogen or organic radical. Depending upon the nature of
R, the sulphonamides are classified as aliphatic, aromatic and heterocyclic. The
aliphatic sulphonamides have not yet become important. Aromatic and
heterocyclic sulphonamides have achieved gread commercial significance. Their
application in bacterial chemotherapy is well known. Considerable interest has
been shown in the chemistry of sulphonamides due to their as antibacterial,
anticancer, antimalarial, antifungal, antispasmodic, anticonvulsant, herbicidal,
antiinflammatory and analytical prepartion.
SYNTHETIC ASPECT
The different methods for the synthesis of sulphonamides have been
described in literature157-159
BIOLOGICAL IMPORTANCE
Many efforts have been undertaken to extend. The activity and reduce
toxicity of sulpha drugs. Monograms and review157-159 surveying various aspect
of sulpha drugs have been published.
W. Loh et al.160 have prepared substituted benzene sulphonyl hydrazones
of 2-piperidine carboxaldehyde-1-oxide (D) which causes disappearance of tumor
64
in 20-80% of Leukemia bearing mice. The antineoplastic activity of these
compounds have been assessed in mice bearing either Leukemia L1210 P388.
M. Kadrikyan et al.161 have synthesised N-(2-benzofuranyl methyl)-N-
propyl-4-propoxy benzensulphonamide-(E) which reduced the blood glucose
content by 20% at 250 mg/kg.
O. Sharipov et. al.162 have studied the comparision of some sulphonamides
with their effect on blood coagulation in vitro. The seven sulphonamides tested,
streptoside was least active in delaying blood coagulation in vitro.
A.  R.  Par ikh and Co workers  synthes ised su lphonamides having




















General structure of sulphonamide are as under.
H. Parekh et al.167 synthesised sulphonamides having-5-substituted 1,3,4-
oxadiazole moiety.
V. Shah et al. synthesised sulphonamides having indole, benzothiazole168




R = -NH, Aryl
X = X =








































General structure of sulphonamide are as under.
THERAPEUTIC IMPORTANCE :
Sulphonamides and their derivatives showed well known therapeutic activity





















































These valid observation prompted us to synthesised some new sulphonamide
derivatives bearing 4-(3H)-quinazolone, phenothiazine and piperazine moiety
in search of pharmaceutical agents having better therapeutic activity. Which have
been described as under.
Section - I : Synthesis and biological screening of 10-N-(Aryl
sulpho)-7-methyl phenothiazine-1-carboxylic acid.
Section - II : Synthesis  and biological  screening of  3-Aryl
sulphonamido-2-[1'-(4"-chlorophenyl)-2'-methyl-
propyl]-quinazolin-4-(3H)-one.
Section - III : Synthesis and biological screening of 1-(Aryl




SYNTHESIS AND BIOLOGICAL SCREENING OF 10-N-(ARYL
SULPHO)-7-METHYL PHENOTHIAZINE-1-CARBOXYLIC ACID.
In view of procuring better therapeutic agents, the preparation of 10-N-
(arylsulpho)-7-methyl phenothiazine-1-carboxylic acid, of type (F) have been
synthesised by the condensation of 7-methyl-phenothiazine-1-carboxylic acid with
aryl sulphonyl chloride.
The constitution of the products were supported by elemental analyses, IR,
NMR, Mass spectral study. The products were screened for their antimicrobial
activity at a concentration of 50 µg. The details have been cited in Part-I, Section-










IR SPECTRAL STUDY OF 10-N-[(3'-CARBOXY PHENYL SULPHO)-7-METHYL-
PHENOTHIAZINE-1-CARBOXYLIC ACID.
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2950 2975–2950 110,111,112
–CH3 C – H str. (sym) 2829 2890–2850 "
C – H def. (asym) 1450 1470–1435 "
C – H def. (sym) 1370 1385–1365 "
Aromatic C–H str. 3060 3080–3030 110,111, 112
C=C Ring Skeletal 1515,1581 1600–1450 "
C–H o.o.p. def. 727,759 760–710 "
C–S–C str. 690 700–600 112
C–N str. 1362 1380–1332 113
Sulphonamide S= O str. (asym) 1330 1370–1300 112
S = O str. (sym) 1163 1180–1140 "
N – H (asym) 3327 3550–3350 113
N – H def. 1610 1650–1550 "
Carboxylic acid C = O 1691 1725–1700 "








NMR SPECTRAL STUDY OF 10-N-(3'-CARBOXYPHENYL SULPHO)-7-METHYL-
PHENOTHIAZINE-1-CARBOXYLIC ACID.
Internal Standard : TMS; Solvent : DMSO  : Instrument : BRUKER Spectrometer (200 MHz)
Signal Signal Position Relative No. Multiplicity Inference
No. (δ ppm) of Protons
1 2.29 3H singlet –CH3
2 6.71 1H doublet Ar–Ha
3 6.78 1H doublet Ar–Hb
4 6.74 1H singlet Ar–Hc
5 7.1–7.3 3H multiplet Ar–Hd,e,f,g
6 7.9 1H singlet Ar–Hh



















































































































Comparable activity with known standard drugs :-
Ampicillin 22 18 19 27 –
Chloramphenicol 24 19 25 26 –
Norfloxacin 24 19 25 26 –
Griseofulvin – – – – 23
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
Antimicrobial activity :-
Conclution
Maximum Antimicrobial activity :-
7
4
B. mega B. subtilis E. coli P. vulgaris A. niger



























SYNTHESIS OF 10-N-(ARYL SULPHO)-7-METHYL PHENOTHIAZINE-
1-CARBOXYLIC ACID.
(A) Synthesis of 2-Carboxy-4'-methyl diphenyl amine.
For synthesis see Part-I, Section-I, Page No.30
(B) Synthesis of 7-Methyl phenothiazine-1-carboxilic acid.
For synthesis see Part-I, Section-I, Page No.30
(C) Synthesis  o f  10-N-[ (3 ' -Carboxy phenyl  sulpho) -7-methyl
phenyothiazine-1-carboxylic acid.
A mixture of 7-methyl phenothiazine-1-carboxilic acid (2.57 g, 0.01 M),
3-carboxy benzene sulphonyl chloride (2.20 g, 0.01 M) and pyridine (20 ml)
was refluxed for 5 hrs at 120oC. The content was cooled and poured into crushed
ice. Neutralised with dilute hydrochloric acid. The content was filtered and washed
with water. The isolated product was crystallised from DMF: water (3 : 1) yield:
70.42% m.p.: 92oC, (Found : C, 57.10; H, 3.37; N, 3.15; C21H15O6NS2
required C, 57.14; H, 3.40; N, 3.17%)
Similarly others 10-N-(Aryl sulpho)-7-methyl phenothiazine-1-carboxylic
acid were synthesised.
The physical constant of the products are recorded in Table No.7.
(D) Ant imicrobial  act iv i ty  o f  10-N-(Aryl  sulpho) -7-methyl
phenothiazine-1-carboxilic acid.
The antimicrobial testing was carried out as described in Part-I, Sction-I,
Page No.31-34.























1 3–COOH.C6H4– C21H15O6NS2 92 70.42 3.17 3.15
2 3–COOH, 4–OH.C6H3– C21H15O7NS2 152 78.58 3.06 3.00
3 3–COOH, 4–Cl.C6H3– C21H14O6NS2Cl 170 75.42 2.94 2.91
4 5–COOH, 2–Cl.C6H3– C21H14O6NS2Cl 145 68.92 2.94 2.92
5 4–Cl.C6H4– C20H14O4NS2Cl 120 80.46 3.24 3.20
6 4–CH3
.C6H4– C21H17O4NS2 54 65.41 3.40 3.38
7 4–NH COCH3
.C6H4– C22H18O5N2S2 160 72.88 6.16 6.12
8 5–COOH, NO2
.C6H3– C21H14O8N2S2 175 80.21 5.76 5.73
9 5–COOH, 2–OCH3
.C6H3 C22H17O7NS2 118 74.29 2.97 2.94
10 5–COOH, 2–CH3
.C6H3 C22H17O6NS2 184 84.42 3.07 3.03
11 3–COOH, 4–OCOCH3
.C6H3– C23H17O8NS2 163 74.88 2.80 2.77
7
7
TABLE NO. 8 : ANTIMICROBIAL ACTIVITY OF 10-N-(ARYLSULPHO)-7-METHYL PHENOTHIAZINE-1-
CARBOXYLIC ACID.
1 3–COOH.C6H4– 10 15 21 13 18
2 3–COOH, 4–OH.C6H3– 22 18 20 10 16
3 3–COOH, 4–Cl.C6H3– 18 22 20 11 20
4 5–COOH, 2–Cl.C6H3– 10 24 24 18 18
5 4–Cl.C6H4– 16 18 15 12 16
6 4–CH3
.C6H4– 19 22 20 15 19
7 4–NH COCH3
.C6H4– 10 15 14 18 18
8 5–COOH, 2NO.C6H3– 10 23 12 14 22
9 5–COOH, 2–OCH3
.C6H3 21 16 17 13 14
10 5–COOH, 2–CH3
.C6H3 18 19 18 21 17
11 3–COOH, 4–OCOCH3
.C6H3– 12 24 10 12 10
Sr. No. R B. mega B. subtilis E. coli P. vulgaris A. niger
1 2 3 4 5 6 7
Antibacterial activity
Zone of inhibition in m.m.
Antifungal activity








Quinazoline-(G) is Benz-1,3-diazine containing-4-hydroxy substituents
serves as nucleus to a host of compounds which are associated with wide spectrum
of physiological activities. They are reported to exhibit properties of both the
keto and enol forms188,190
The work presented in this part is in connections with the study of certain




















The 4-ketoquinazolines have both animal and plant origin. The glomerin,
homoglomerin (H) are the quinazolinone derivatives produced by European
millipede glomeris marginata.
Extensive studies have been made in the f ie ld of  synthesis  of  4-
ketoquinazolines, several methods have been reported in literature.191-223
K. Kang224 have been synthesised 3-(1-methylethyl)-(1H)-2,1,3-
benzothiaidiazine-4-(3H)-one 2,2-dioxide (Bentazone)-(I) gave good herbicidal



















A. R. Parikh et al.225,226 have been synthesised 4-(3H)-quinazolones
derivatives and also evaluated its antimicrobial activity.
V. H. Shah et al. 227 have been synthesised 4-(3H)-quinazolone derivatives
and also evaluated its antimicrobial activity.
THERAPEUTIC IMPORTANCE :
4-(3H)-quinazolone derivatives showed a wide range of therapeutic activity,


























XX = - CH3
Y = - H
Z = - NH-SO2-R
X = - CH3
Y = - H


















In view of procuring better therapeutic agents. The synthesis of 3-aryl
sulphonamido-2-[1'-(4"-chlorophenyl)-2'-methyl-propyl]-quinazolin-4-(3H)-one.
of type (V) have been synthesised by the condensation of 3-amino-2-[1'-(4"-
chloro phenyl)-2-methyl propyl]-quinazolin-4-(3H)-one with aryl sulphonyl
chloride. The latter was synthesised by 2-{[2'-(4"-chloro phenyl)-3'-methyl
butanoyl]amino} benzoic acid with hydrazine hydrate. 2-{[2'-(4"-chlorophenyl)-
3'-methyl butanoyl]amino} benzoic acid have been synthesised by the reaction
of 2-amino benzoic acid with 3-methyl-2-(4'-chloro phenyl)-butanoyl chloride
The consitution of the products were supported by elemental analyses, IR,
NMR, Mass spectral study. The products were screened for antimicrobial activity











Type (V) R = Aryl
83
IR SPECTRAL STUDY OF 3-[(5'-CARBOXY-2'-NITROPHENYL)SULPHONAMIDO]-2-[1"-
(4'''-CHLOROPHENYL)-2"-METHYL PROPYL]-QUINAZOIN-4-(3H)-ONE.
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2962 2975–2950 110,111,112
–CH3 C – H str. (sym) 2871 2890–2860 "
C – H def. (asym) 1467 1470–1435 "
C – H def. (sym) 1350,1388 1385–1365 "
doublet isopropyl
Aromatic C–H str. 3045 3080–3030 110,111,112
C–H i. p. def. 1294 1300–1100 "
C–H o.o.p. def. 800 832–802 "
C = C Ring Skeletal 1488,1539 1600–1450 "
Sulphonamide S= O str. (asym) 1350 1370–1300 111
S = O str. (sym) 1164 1180–1140 "
N – H (str) 3323 3500–3300 112
N – H bending 1583 1650–1550 "
C=O str. (ketone) 1697 1720–1685 "
C=N str. bending 1604 1690–1640 "
C–N str. 1109 1220–1020 "
–OH 3410 3500–3300 "
Nitro N=O str. 1539.5 1560–1540 "
Halide C–Cl str. 715 800–600 "













NMR SPECTRAL STUDY OF 3-(5'-CARBOXY-2'-NITROPHENYL)-SULPHONAMIDO-2-
[1"-(4"-CHLOROPHENYL)-2"-METHYL PROPYL]-QUINAZOLIN-4-(3H)-ONE
85
Internal Standard : TMS; Solvent : DMSO   : Instrument : BRUKER Spectrometer (200 MHz)
Signal Signal Position Relative No. Multiplicity Inference
No. (δ ppm) of Protons
1 0.9 6H doublet –CH
3
a
2 1.06 1H multiplet –CH b
3 0.7 1H doublet –CH c
4 8.01–8.6 4H multiplet Ar–Hd
5 7.42 4H singlet Ar–He
6 8.94 1H doublet Ar–Hf
7 8.4 1H doublet Ar–Hg
8 8.96 1H siglet Ar–Hh
9 3.33 1H singlet –NH































































































































.C6H3–(21) – – – –
5–COOH, 2–OCH3
.C6H3–(21) – – – –
Comparable activity with known standard drugs :-
Ampicillin 22 18 19 27 –
Chloramphenicol 24 19 25 26 –
Norfloxacin 24 19 25 26 –
Griseofulvin – – – – 23
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
Antimicrobial activity :-
Conclution
Maximum Antimicrobial activity :-
8
8
B. mega B. subtilis E. coli P. vulgaris A. niger
R R R R R





































SYNTHESIS OF 3-ARYL SULPHONAMIDO-2- [1 ' - (4" -CHLORO
PHENYL)-2'-METHYL-PROPYL]-QUINAZOLIN-4-(3H)-ONE.
(A) Synthesis of 2-{[2'-(4"-Chlorophenyl)-3'-methyl butanoyl]amino}-
benzoic acid.
A mixture of 2-amino benzoic acid (1.37 g, 0.01 M), 3-methyl-2-(4'-chloro
phenyl)butanoyl chloride (2.30 ml 0.01 M) ethanol (10 ml) and pyridine (0.5
ml) was  refluxed at 4 hrs at 120oC temp. The product was cooled and poured on
to crushed ice, filtered and washed with cold water and dried. The isolated product
was crystallised from ethanol. Yield: 79.00%, m.p.: 110oC. (Found : C, 65.00; H,
5.35; H, 4.20; C18H18O3NCl required C, 65.15 ; H, 5.42 ; N, 4.22%).
(B) Synthesis of 3-Amino-2-(1'-(4"-chlorophenyl)-2'-methyl propyl)
quinazolin 4-(3H)-one.
A mixture of 2-{[2'-(4"-chloro phenyl)-3'-methyl butanoyl]amino}-benzoic
acid (3.31 gm, 0.01 M) hydrazine hydrate (1.0 ml, 0.01 M) ethanol (20 ml) and
pyridine (0.5 ml) was refulxed for 4 hrs at 120o C. The contents were cooled and
poured onto crushed ice, filtered and washed with water. The isolated product
was crystallised from ethanol. Yield: 85.60%, m.p.: 80oC. (Found : C, 65.87; H,
5.45; N, 12.80, C18H18ON3Cl required. C, 65.95; H, 5.49; N, 12.82%).
(C) Synthesis of 3-(5' -Carboxyphenyl)-sulphonamido-2-[1' ' - (4 ' ' -
chlorophenyl)-2''-methyl propyl] quinazolin-4(3H)-one.
A mixture of 3-amino 2-[1'-(4"-chloro phenyl)-2'-methylpropyl] quinazolin
4(3H)-one (3.27 g, 0.01 M) and 5-carboxy-2-nitro benzene sulphonayl chloride
(2.65 g, 0.01 M) pyridine (10 ml) was refluxed for 5 hrs at 120o C. The contents
were cooled and poured onto crushed ice, nutrulized with dilute hydrochloric
acid, filtered and washed with water. The isolated product was crystallised from
90
ethanol. Yield 78.92%, m.p. 142oC. (Found : C, 53.85; H, 3.70; N, 10.01,
C25H21O7N4SCl required C, 53.90; H, 3.77; N, 10.06).
Similarly other 4-(3H)-quinazolone were synthesised. The physical constants
of the products are recorded in Table No. 9.
(D) Ant imicrobial  act iv i ty  o f  3 -Ar yl  sulphonamido-2- [1 ' - (4" -
chlorophenyl)-2'-methyl propyl]-quinazolin-4-(3H)-one.
The antimicrobial testing was carried out as described in Part-I, Section-I,
























1 3–COOH, 4–OH.C6H3– C25H22O6N3SCl 106 48.20 7.96 7.90
2 5–COOH, 2–Cl.C6H3– C25H21O5N3SCl2 132 72.78 7.69 7.65
3 3–COOH, 4–Cl.C6H3– C25H21O5N3SCl2 126 68.42 7.69 7.60
4 4–Cl.C6H4– C24H21O3N3SCl2 91 65.44 8.36 8.35
5 5–COOH, 2–NO2
.C6H3– C25H21O7N4SCl 142 78.92 10.06 10.01
6 4–NHCOCH3
.C6H4– C26H25O4N4SCl 126 70.48 10.67 10.63
7 3–COOH, 4–OCOCH3
.C6H3– C27H24O7N3SCl 254 62.62 7.37 7.30
8 5–COOH, 2–OCH3
.C6H3– C26H24O6N3SCl 88 68.42 7.75 7.71
9 5–COOH, 2–CH3
.C6H3– C26H24O5N3SCl 128 89.42 7.99 7.96
9
2
TABLE NO. 10 : ANTIMICROBIAL ACTIVITY OF 3–ARYL SULPHONAMIDO-2-[1'-(4"-CHLOROPHENYL)-2'-
METHYL PROPYL]-QUINAZOLIN-4(3H)-ONE.
1 3–COOH, 4–OH.C6H3– 24 15 20 12 11
2 5–COOH, 2–Cl.C6H3– 12 14 10 10 12
3 3–COOH, 4–Cl.C6H3– 21 17 19 14 14
4 4–Cl.C6H4– 22 14 19 11 10
5 5–COOH, 2–NO2
.C6H3– 21 19 12 22 20
6 4–NHCOCH3
.C6H4– 18 21 16 13 15
7 3–COOH, 4–OCOCH3
.C6H3– 16 10 14 12 10
8 5–COOH, 2–OCH3
.C6H3– 21 14 12 13 17
9 5–COOH, 2–CH3
.C6H3– 12 17 15 16 13
Sr. No. R B. mega B. subtilis E. coli P. vulgaris A. niger
1 2 3 4 5 6 7
Antibacterial activity
Zone of inhibition in m.m.
Antifungal activity




SYNTHESIS AND BIOLOGICAL SCREENING OF 1-(ARYLSULPHO)-
4-[(4'CHLOROPHENYL) (PHENYL) METHYL] PIPERAZINE.
In view  procuring of better therapeutic agents of sulphonamide derivatives,
the synthesis of 1-(arylsulpho)-4-[(4'-chlorophenyl) (phenyl) methyl]-piperazine
of type - (VI) have been under taken by the condensation of 4-N-[(4'-
chlorophenyl) (phenyl) methyl]-piperazine with aryl sulphonyl chloride.
The constitution of the products have been characterised by elemental
analyses, IR, NMR and Mass spectral study. The products were screened for their







Type (VI) R = Aryl
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IR SPECTRAL STUDY OF 1-[(2'-METHOXY-5'-CARBOXY PHENYL)SULPHO-4-[(4"-
CHLOROPHENYL) (PHENYL) METHYL]-PIPERAZINE.
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2958 2975–2950 110,111,112
–CH3 C – H str. (sym) 2829 2890–2860 "
C – H def. (asym) 1467 1470–1435 "
C – H def. (sym) 1388 1385–1365 "
Aromatic C–H str. 3065 3080–3030 110,111, 112
C–H o.o.p. def. 800 832–802 "
C = C Ring Skeletal 1488,1539 1635–1495 "
Sulphonamide S= O str. (asym) 1350 1370–1300 112
S = O str. (sym) 1164 1180–1140 "
Piperazine C – N str. 1350 1380–1332 "
Moiety
Halide C–Cl str. 715 800–600 111
Ether C–O–C str 1164 1200–1100 "
Carboxylicacid >C=O 1691 1725–1700 "









NMR SPECTRAL STUDY OF 1-[(2'-METHOXY-5'-CARBOXY PHENYL)SULPHO-4-[(4"-
CHLOROPHENYL)(PHENYL)METHYL]-PIPERAZINE.
Internal Standard : TMS; Solvent : DMSO   : Instrument : BRUKER Spectrometer (200 MHz)
Signal Signal Position Relative No. Multiplicity Inference
No. (δ ppm) of Protons
1 3.8 3H singlet –OCH3
2 7.36 5H singlet Ar–Ha
3 7.14 2H doublet Ar–Hbb'
4 7.29 2H doublet Ar–Hcc'
5 8.09 2H doublet Ar–Hd
6 8.25 2H doublet Ar–He
7 8.13 1H singlet Ar–Hf






















































































Comparable activity with known standard drugs :-
Ampicillin 22 18 19 27 –
Chloramphenicol 24 19 25 26 –
Norfloxacin 24 19 25 26 –
Griseofulvin – – – – 23
B. mega B. subtilis E. coli P. vulgaris A. niger
R R R R R
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
Antimicrobial activity :-
Conclution






























SYNTHESIS OF 1-(ARYLSULPHO)-4-[(4'-CHLOROPHENYL) (PHENYL)
METHYL] PIPERAZINE.
(A) Synthesis of 4-Chloro benzophenone.
For the synthesis see Part-I, Section-III, Page No.59
(B) Synthesis of 1-(4'-Chloro phenyl) (phenyl) methanol.
For the synthesis see Part-I, Section-III, Page No.59
(C) Synthesis of (4'-Chloro phenyl) (phenyl) methyl chloride.
For the synthesis see Part-I, Section-III, Page No.59
(D) Synthesis of [(4'-Chloro phenyl) (phenyl) methyl] piperazine.
For the synthesis see Part-I, Section-III, Page No.59
(E) Synthesis of 1-(2'-Methoxy-5'-carboxyphenyl sulpho)-4-[(4"-
chlorophenyl) (phenyl) methyl]-piperazine.
A mixture of [(4'-chloro phenyl) (phenyl) methyl] piperazine (2.86 g, 0.01
M) 2-methoxy-5-carboxy benzene sulphonyl chloride (2.50 g, 0.01M) pyridine
(10ml) was refluxed at 120o C for 4 hours. The content was cooled and poured
onto crushed ice, neutralised with hydrochloric acid. The isolated product was
crystalised from ethanol. Yield : 84.18%; m.p.: 98oC. (Found : C, 64.00; H, 5.30;
N, 5.94; C25H25O5N2Cl) required : C, 64.03 ; H, 5.33; N, 5.97%).
Similary other sulphonamide were synthesised. The physical constant are
recorded in Table No. 11.
(F) Antimicrobial activity of 1-(Arylsulpho)-4-[(4'-chlorophenyl)
(phenyl) methyl] piperazine.
The antimicrobial testing was carried out as described in Part-I, Section-I,
























1 3–COOH.C6H5– C24H23O4N2Cl 248 74.98 6.38 6.35
2 3–COOH, 4–OH.C6H3– C24H23O5N2Cl 110 68.19 6.16 6.14
3 5–COOH, 2–OH.C6H3– C24H23O5N2Cl 102 57.76 6.16 6.12
4 3–COOH, 4–Cl.C6H3– C24H22O4N2Cl2 64 58.49 5.91 5.89
5 5–COOH, 2–Cl.C6H3– C24H22O4N2Cl2 214 68.16 5.91 5.86
6 4–Cl.C6H4– C24H22O2N2Cl2 86 77.65 6.52 6.49
7 3–COOH, 4–OCOCH3
.C6H3– C26H25O6N2Cl 202 60.12 5.63 5.60
8 5–COOH, 2–NO2
.C6H3– C24H22O6N3Cl 192 75.43 8.68 8.64
9 5–COOH, 2–OCH3
.C6H3– C25H25O5N2Cl 98 84.18 5.97 5.94
10 5–COOH, 2–CH3
.C6H3– C25H25O4N2Cl 121 81.28 6.18 6.16
11 4–CH3
.C6H4 C24H25O2N2Cl 218 57.20 6.85 6.81
12 4–NHCOCH3




TABLE NO. 12 : PHYSICAL CONSTANTS OF 1-[ARYLSULPHON]-4-[(4"-CHLOROPHENYL) (PHENYL) METHYL]
PIPERAZINE.
1 3–COOH.C6H5– 14 19 18 17 18
2 3–COOH, 4–OH.C6H3– 16 14 16 20 16
3 5–COOH, 2–OH.C6H3– 15 14 18 17 13
4 3–COOH, 4–Cl.C6H3– 18 16 21 20 20
5 5–COOH, 2–Cl.C6H3– 20 18 17 20 16
6 4–Cl.C6H4– 12 16 13 21 12
7 3–COOH, 4–OCOCH3
.C6H3– 21 14 12 14 19
8 5–COOH, 2–NO2
.C6H3– 20 18 19 16 18
9 5–COOH, 2–OCH3
.C6H3– 14 16 16 18 11
10 5–COOH, 2–CH3
.C6H3– 17 20 21 16 12
11 4–CH3
.C6H4 14 19 18 13 14
12 4–NHCOCH3
.C6H4– 13 20 17 15 13
Sr. No. R B. mega B. subtilis E. coli P. vulgaris A. niger
1 2 3 4 5 6 7
Antibacterial activity
Zone of inhibition in m.m.
Antifungal activity







SUTDIES ON ARYL AMIDES
INTRODUCTION
The aryl substitution products of ammonia are arylamides (R-CONH-)
derivatives. Amides (-CO-NH-) derivatives, urea (-NH-CO-NH-)derivatives
diamides (-CO-NH-CO-NH-) derivatives of carbonic acid are several naturally
occurring products. The proteins and peptides are linear structure of cyclic
polyamides. The alkaloids of pepper, piperine and chavicine are N-substituted
amide, of unsaturated acids. Amides derived from polyacetylenic acids have been
isolated from certain fungi.275 N-Isobutyl amide of certain highly unsaturated
aliphatic acid shows insecticidal activity276 and occur in plants.
SYNTHETIC ASPECT :
Several methods are reported in literature277,278 for the preparation of
aryl acetamides.
THERAPEUTIC IMPORTANCE :
Amides  ary l  amides ,  he t rocyc l i c  a ry l  amide der iva t ives  showed











Bartuleweiz et al.289 have assessed arylamides as potential antitumor and
antibiotics. Dekeysefi et al.290 have prepared novel arylamide derivatives (J)
and studied their immunomodulator activity.
Sanderson Philip E. J. & Co-workers291 have synthesised arylamides and
studies their biological activity moloney Brian Anthony et al.292 have synthesised
& studied their pharmacological activity which have been found as an antiulcer
agent. Foster James and Co-workers293 have synthesised some new arylamides
as potent anticonvulsant. A. R. Mulik and co-workers294 have studied some
arylamides showing antibiotic activity. Bridge Gory et al.295 have prepared some
aryl amides and reported their anti-HIV activity. In other study, Laura and co-
workers296 have shown arylamide derivatives analogues as bacterial inhibitors.




















Cudahy et al.298 have synthesised arylamides as antiviral Lau Jespers et
al.299 have reported arylamides as glucokinase (GK) activators. A. Flohr et al.300
have synthesised arylamides as human adenosine receptor.
Parikh et al.301-303 have synthesised various arylamide derivatives as
antimicrobial agents. Some arylamides having quinoline moieties are also
reported304,305. The general structure and some substituents used are given
below.
T. Kenochi et al.306 have been reported carboxamides derivatives as PAF
antagonist.
Q. Liyuan et al307 have been synthesis of high purity 1,4-bis (p-
aminobenzoyl)-piperazine.






























Y. Takashi et al.308 have been reported arylamides derivatives gave receptor
antagonistic activty.
H. Dirk et al.309 have been reported amide derivatives gave fibrinogen
receptor antagonist.































SYNTHESIS AND BIOLOGICAL SCREENING OF 10-N-(AROYL)-7-
METHYL PHENOTHIAZINE-1-CARBOXILIC ACID.
Aryl amides represent one of the important classes of compounds having a
broad spectrum of bilogical activities. with an attempt to getting better therapeutic
agents, the preparation of the arylamides 10-N-(aroyl)-7-methyl phenothaizine-
1-carboxylic acid of type-(VII) have been synthesised by the condensation of 7-
methyl pehnothiazine-1-carboxylic acid with aroyl chloride.
The constitution of the products were supported by elemental analyses, IR,
NMR and Mass spectral studies. The products were screened for antimicrobial
activity at a concentration of 50 mg.






Type (VII) R = Aryl
109
IR SPECTRAL STUDY OF 10-N- (3 ' ,5 ' -DIMETHYL BENZOYL) -7 -METHYL-
PHENOTHIAZINE-1-CARBOXYLIC ACID.
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2922 2975–2950 110,111,112
C – H str. (sym) 2882 2890–2860 "
–CH3 C – H  bend. 1473 1470–1435 "
Aromatic C–H str. 3068 3080–3030 110,111, 112
C = C Ring Skeletal 1512,1564,1598 1600–1400 "
C–H o.o.p. def. 817 832–802 "
C–S–C str. 686 700–600 "
C–N str. 1352 1380–1332 113
Amide C= O str. 1730 1760–1655 113









NMR SPECTRAL STUDY OF 10-N-(3 ' ,5 ' -DIMETHYL BENZOYL)-7-METHYL-
PHENOTHIAZINE-1-CARBOXILIC ACID.
Internal Standard : TMS; Solvent : CDCl3   : Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference
No. (δ ppm) of Protons
1 2.29–2.53 9H singlet Ar–CH3
2 7.2 1H doublet Ar–Ha
3 7.5 1H doublet Ar–H b
4 7.9 1H singlet Ar–Hc
5 8.04–8.2 3H singlet Ar–Hd
6 8.6 2H singlet Ar–He
7 6.9 1H singlet Ar–Hf






































































































































.C6H3–(20) C6H5–CH=CH–(22) C6H5–CH=CH–(19) 4–CH3
.C6H4–(20)
– – – – 3,5–(CH3)2
.C6H3–(22)
– – – – C6H5–CH=CH–(20)
Comparable activity with known standard drugs :-
Ampicillin 22 18 19 27 –
Chloramphenicol 24 19 25 26 –
Norfloxacin 24 19 25 26 –
Griseofulvin – – – – 23
B. mega B. subtilis E. coli P. vulgaris A. niger
R R R R R
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
Antimicrobial activity :-
Conclution


































SYNTHESIS OF 10-N-(AROYL)-7-METHYL PHENOTHIAZINE-1-
CARBOXYLIC ACID.
(A) Synthesis of 2-Carboxy-4'-methyl diphenyl amine.
For synthesis see Part-I, Section-I, Page No.30
(B) Synthesis of -7-Methyl phenothiazine-1-caroxylic acid.
For synthesis see Part-I, Section-I, Page No.30
(C) Synthesis  o f  10-N-(3 ' ,5 ' -Dimethyl  benzoyl ) -7-methyl -
phenothiazine-1-carboxilic acid.
A mixture of 7-methyl phenothiazine-1-carboxylic acid (2.33 g, 0.01 M) and
3',5'-dimethyl benzoyl chloride (1.68 g, 0.01 M) pyridine (20 ml). The reaction
mixture was refluxed at 120oC for 5 hrs. The reaction mixture was poured onto
crushed ice. The isolated product was crystalised with dioxane. yield: 85.40%,
m.p.: 202oC, (Found, C, 7.90; H, 4.86 ; N, 3.95; C23H19O3NS required C, 70.95
; H,4.88 ; N,3.57%)
Similarly other aroyl amides were prepard. The physical constants of the
products are recorded in Table No. 13.
(D) Antimicrobial activity of 10-N-(Aroyl)-7-methyl phenothiazine-1-
carboxylic acid.
The antimicrobial testing was carried out as described in Part-I, Section-I,
Page No.31-34.
The zone of inhibition of the test solutions are recorded in Table No. 14.
116
SECTION - II
SYNTHESIS AND BIOLOGICAL SCREENING OF 3-AROYL AMINO-2-
[1'-(4"-CHLOROPHENYL)-2'-METHYL PROPYL] QUINAZOLIN-4-(3H)-
ONE.
Aryl amide derivatives represents one of the modest classess of compounds
possessing wide range of therapeutic activities. In view of getting to synthesis 3-
aroylamino-2-[1'-(4"-chloro phenyl)-2'-methyl propyl] quinazolin-4-(3H)-one of
type-(VIII) have been undertaken by the condensation of 3-amino-2-[1'-(4"-chloro
phenyl)-2'-methyl propyl]-quinazolin-4-(3H) one with aroyl chloride.
The constitution of the products were supported by elemental analyses, IR,
NMR and Mass spectral studies. The products were screened for antimicrobial
activity at a concentration of 50 mg.









Type (VIII) R = Aryl
119
IR SPECTRAL STUDY OF 3-(4'''-NITROBENZAMIDO)-2-[1'-(4"-CHLORO PHENYL)-2'-
METHYL PROPYL]QUINAZOLIN-4-(3H)-ONE.
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 3010 2975–2950 110,111,112
–CH3 C – H str. (sym) 2852 2890–2860 "
C – H def. (asym) 1471 1470–1435 "
C – H def. (sym) 1350,1388 1385–1365 "
doublet isopropyl
Aromatic C–H str. 3062 3080–3030 110,111, 112
C=C Ring Skeletal 1490–1589 1600–1450 "
C–H o.o.p. def. 816 832–802 "
Amide C= O str. 1693 1760–1655 113
N – H syr (asym). 3402 3550–3300 "
C=N bending 1604 1690–1940 "
C – N str. 1137 1220–1020 "
Nitro N=O str. 1525 1560–1540 "












NMR SPECTRAL STUDY OF 3-(4'''-NITROBENZAMIDO)-2-[1'-(4"-CHLOROPHENYL)-
2'-METHYLPROPYL]-QUINAZOLIN-4-(3H)-ONE.
Internal Standard : TMS; Solvent : CDCl3   : Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference
No. (δ ppm) of Protons
1 0.09 6H doublet –CH3a
2 1.06 1H multiplet –CHb
3 0.7 1H doublet –Chc
4 8.1–8.3 4H multiplet Ar–Hd
5 7.3–7.5 4H singlet Ar–He
6 8.38 2H doublet Ar–Hf
7 8.33 2H doublet Ar–Hg

















































































































































Comparable activity with known standard drugs :-
Ampicillin 22 18 19 27 –
Chloramphenicol 24 19 25 26 –
Norfloxacin 24 19 25 26 –
Griseofulvin – – – – 23
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
Antimicrobial activity :-
Conclution




B. mega B. subtilis E. coli P. vulgaris A. niger
R R R R R






































SYNTHESIS OF 3-AROYL AMINO-2-[1'-(4"-CHLOROPHENYL)-2'-
METHYL PROPYL] QUINAZOLIN-4-(3H)-ONE.
(A) Synthesis of 2-{[2'(4"-Chloro phenyl)-3'-methyl butanoyl] amino}
benzioc acid.
For synthesis see Part-II, Section-II, Page No.90
(B) Synthesis  o f  3-Amino 2- [1 ' - (4" -Chlorophenyl ) -2 ' -methyl
propyl]quinazolin-4(3H)-one.
For synthesis see Part-II, Section-II, Page No.90
(C) Synthesis of 3-(4'"-Nitro benzamido)-2-[1'-(4"-chloro phenyl)-2'-
methyl propyl]-quinazolin-4-(3H)-one.
A mixture of 3-amino-2-[1'-(4"-chloro phenyl)-2'-methyl propyl]-quinazolin-
4-(3H)-one (2.92 g, 0.01 M) 4-nitrobenzoyl chloride (1.85 g, 0.01 M) and pyridine
(10 ml). The reaction mixture was refluxed at 120oC temp for 5 hrs. The content
was cooled and poured onto crushed ice. filtered and dried. The isolated products
was crystalised from ethanol. Yield : 68.92%, m.p.: 265oC (Found : C,63.19  ;
H,  4.39; N,11.75  ; C25H21O4N4 Cl required : C,63.22 ; H,4.42 ; N,11.80%)
Similarly other aroyl amides were prepared. the physical constants are
recorded in Table No. 15.
(D) Antimicrobial activity of 3-Aroylamino-2-[1'-(4"-chlorophenyl)-2'-
methyl propyl]-quinazolin-4-(3H)-one.
The antimicrobial testing was carried out as described in Part-I, Section-I,
Page No.31-34.























1 C6H5– C25H22O2N3Cl 119 90.42 9.73 9.70
2 2–Cl.C6H4– C25H21O2N3Cl2 132 68.92 9.01 9.00
3 4–Cl.C6H4– C25H21O2N3Cl2 195 82.51 9.01 8.95
4 2,4–(Cl)2
.C6H3– C25H20O2N3Cl3 148 82.22 8.39 8.31
5 C6H5–CH=CH– C27H24O2N3Cl 194 62.34 9.18 9.09
6 4–NO2
.C6H4– C25H21O4N4Cl 265 68.92 11.80 11.75
7 3,5–(NO2)
.C6H3– C25H20O6N5Cl 68 76.49 13.42 13.33
8 4–CH3
.C6H4– C26H24O2N3Cl 64 64.82 9.42 9.32
9 4–OCH3




TABLE NO. 16 : ANTIMICROBIAL ACTIVITY OF 3-AROYL AMINO-2-[1'-(4"-CHLOROPHENYL)-2'-METHYL
PROPYL] QUINAZOLIN-4-(3H)-ONE.
1 C6H5– 16 18 12 19 20
2 2–Cl.C6H4– 20 18 21 14 19
3 4–Cl.C6H4– 15 21 18 17 21
4 2,4.(Cl)2–C6H3– 19 14 16 16 20
5 C6H5–CH=CH– 18 20 22 20 19
6 4–NO2
.C6H4– 16 14 18 16 10
7 3,5–(NO2)
.C6H3– 14 19 20 21 16
8 4–CH3
.C6H4– 22 18 19 19 22
9 4–OCH3
.C6H4– 14 16 18 16 19
Sr. No. R B. mega B. subtilis E. coli P. vulgaris A. niger
1 2 3 4 5 6 7
Antibacterial activity
Zone of inhibition in m.m.
Antifungal activity





SYNTHESIS AND BIOLOGICAL SCREENING OF 1-N-(AROYL)-4-[(4'-
CHLOROPHENYL) (PHENYL) METHYL]-PIPERAZINE.
Piperazine and 4-[(4'-chloro phenyl) (phenyl) methyl]-piperazine and its
derivatives gave better therapeutic activity with a view of procuring to synthesis
of 1-N-(aroyl)-4-[(4'-chlorophenyl) (phenyl) methyl]-piperazine of type-(IX) have
been synthesised by the condensation of 4-[(4'-chlorophenyl) (pheyl)-methyl]-
piperazine with aroyl chloride.
The constitution of the products were supported by elemental analyses, IR,
NMR and Mass spectral data. The products were screended for antimicrobial






Type (IX) R = Aryl
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IR SPECTRAL STUDY OF 1-N-(PHENYL-2"-PROPENE-1"-ONE)-4-[(4'-CHLOROPHENYL)
(PHENYL)-METHYL]-PIPERAZINE.
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2852 2975–2950 110,111,112
–CH2 C – H Bend 1315 1350–1300 "
C–H str. Alkene 3070 3100–3000 "
Aromatic C–H str. 3050 3080–3030 "
C = C Ring Skeletal 1475,1585 1600–1450 "
C–H o.o.p. def. 812 832–802 "
Amide C= O str. 1691 1760–1655 113
Piperazine C – N str. 1315 1360–1310 "
moiety





NMR SPECTRAL STUDY OF 1-N- (PHENYL-2" -PROPENE-1" -ONE) -4 - [ (4 ' -
CHLOROPHENYL) (PHENYL)-METHYL]-PIPERAZINE.
131
Internal Standard : TMS; Solvent : DMSO   : Instrument : BRUKER Spectrometer (200 MHz)
Signal Signal Position Relative No. Multiplicity Inference
No. (δ ppm) of Protons
1 7.1–7.40 5H singlet Ar–Ha
2 7.38 2H doublet Ar–Hbb'
3 7.5 2H doublet Ar–Hcc'
4 7.9 5H singlet Ar–Hd
5 4.9 1H doublet Ar–He vinylic
6 4.3 1H doublet Ar–Hf vinyic

























































































.C6H4–(21) C6H5–CH=CH–(18) – 4–CH3
.C6H4–(19) 4–OCH3
.C6H4–(21)
Comparable activity with known standard drugs :-
Ampicillin 22 18 19 27 –
Chloramphenicol 24 19 25 26 –
Norfloxacin 24 19 25 26 –
Griseofulvin – – – – 23
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
Antimicrobial activity :-
Conclution




B. mega B. subtilis E. coli P. vulgaris A. niger




























SYNTHESIS OF 1-N-(AROYL)-4-[(4'-CHLOROPHENYL) (PHENYL)
METHYL]-PIPERAZINE.
(A) Synthesis of 4-Chlorobenzophenone.
For see Part-I, Section-III, Page No. 59
(B) Synthesis of 1-(4'-chloro phenyl) (phenyl) methanol.
For see Part-I, Section-III, Page No. 59
(C) Synthesis of (4'-chloro phenyl) (phenyl) methyl chloride.
For see Part-I, Section-III, Page No. 59
(D) Synthesis of [(4'-chloro phenyl) (phenyl) methyl] piperazine.
For see Part-I, Section-III, Page No. 59
(E) Synthesis of 1-N-(phenyl-2"-propene-1"-one)-4-[(4'-chlorophenyl)
(phenyl) methyl]-piperazine.
A mixture of 4-[(4'-chlorophenyl) (phenyl)-methyl]-piperazine (2.86 g, 0.01
M) cinnamoyl chloride (1.38 g, 0.01 M) and pyridine (10  ml) was refluxed for 4
hrs at 120oC. The content was cooled and poured into crushed ice, filtered and
washed with water. The isolated product was crystallised from ethanol. Yield :
79.82%, m.p. 49oC (Found : C, 74.87; H, 5.95; N, 6.69; C26H25ON2Cl required
C, 74.90; H, 6.00; N, 6.72%).
Similarly others aroyl amide were synthesised. The physical constants of
the products are recorded in Table No. 17.
(F) Antimicrobial activity of 1-N-(Aroyl)-4-[(4'-chlorophenyl) (phenyl)
methyl]-piperazine.
The antimicrobial testing was carried out as described in Part-I, Section-I,























1 C6H5– C24H23ON2Cl 63 72.83 7.17 7.13
2 2–Cl.C6H4– C24H22ON2Cl2 54 68.01 6.58 6.57
3 4–Cl.C6H4– C24H22ON2Cl2 42 74.98 6.58 6.56
4 2,4–(Cl)2
.C6H3– C24H21ON2Cl3 48 70.00 6.09 6.07
5 4–NO2
.C6H4– C24H22O3N3Cl 58 69.92 9.64 9.63
6 3,5–(NO2)2
.C6H3– C24H21O5N4Cl 80 78.12 11.65 11.61
7 C6H5–CH=CH– C26H25ON2Cl 49 79.82% 6.72 6.69
8 4–OCH3
.C6H4– C25H25O2N2Cl 94 74.84 6.65 6.62
9 4–CH3




TABLE NO. 18 : ANTIMICROBIAL ACTIVITY OF 1-N-(AROYL)-4-[(4'-CHLOROPHENYL)(PHENYL)METHYL]-
PIPERAZINE.
1 C6H5– 19 16 18 19 17
2 2–Cl.C6H4– 18 17 16 18 19
3 4–Cl.C6H4– 17 14 14 12 16
4 2,4–(Cl)2
.C6H3– 19 15 17 15 18
5 4–NO2
.C6H4– 15 16 18 14 18
6 3,5–(NO2)2
.C6H3– 20 19 16 18 19
7 C6H5–CH=CH– 19 18 16 17 21
8 4–OCH3
.C6H4– 21 17 22 20 21
9 4–CH3
.C6H4– 12 14 17 19 19
Sr. No. R B. mega B. subtilis E. coli P. vulgaris A. niger
1 2 3 4 5 6 7
Antibacterial activity
Zone of inhibition in m.m.
Antifungal activity







STUDIES ON  5-OXO-IMIDAZOLINES
INTRODUCTION
5-Oxo-imidazolines is a five membered heterocycle having two nitrogen in
the 1 and 3-posistion and carbonyl group at 5-position-(L).
The discovery of the 2-substituted-5-oxo-imidazolines dates back to the year
1888, when A. Hoffmann311 prepared 2-methyl-5-oxo-imidazolines (lysidine)
by heating N'-diacetyl ethylendiamine in a stream of dry hydrogen chloride
A. Ledenburg312 has prepared the same compound by fusing two equivalents
of sodium acetate with one equivalent of ethylene diaminedihydro chloride
dif ferent methods for the synthesis of imidazol inones are avai lable in
literature.313-316
MECHANISM :
In present study aromatic aldehyde were condensed with benzoyl glycine
in presence of anhydrous sodium acetate and acetic anhydride to get azlactones/
oxazolinones.317
Azlectones reacts with variety of compounds such as water, alcohols, amines

























R = Aryl        X = C 6H5 / CH3
(CH3CO)2O
R-CHO +
condensat ion of  az lactone and pr imary amine can be converted into
imidazolinones as shown in reactions.
The ring closure can be effected under a variety of conditions, subsituted
anilides have been converted into imidazolinones by the reaction of POCl3. In
order to get variety of useful pharmacol important compounds, reaction of
azlactones have been extensively investigated with different type of compounds
such as alcohols318, thiophenols319, hydrazine hydrate320, aromatic amino
acids, phenyl hydrazine321 and ammonia.
SYNTHETIC ASPECT :
Reaction of azlactone with different aromatic amines have attracted a great
attention nowadays because of the interesting nature of resulting compounds.
Their applications and their agrochemical and therapeutic activities. Different
methods have been documented for the synthesis of imidazolinones in
litereature.322-324
V. H. Shah et al. have been synthesised Imidazolinones having dichloran325

























R' - NH2, Dry C5H5N / Abs. C2H5OH, K2CO3
General structure of imidazolinone are as under.
THERAPEUTIC IMPORTANCE
A. Persual of literature reveals that various imidazolinones have resulted in
many potential drugs and are known to possess a broad therapeutic activities,
which are shown as under.
(a) Bactericidal activity329-332
(b) Anticonvulsant activity333-338
(c) Potent CNS depressant activity339-342
(d) Sedatives and hypnotic activity343
(e) Monoamino oxidase (MAO) inhibitory344-346
(f) Hypotensive activity347-349
(g) Potent antiparkinson activity350-354






X = X =


































(k) Antipyretic and analgesic activity358-359
(l) Antiinflammatory activity360-362
It was considered worthwhile to synthesis 5-oxo-imidazolines derivatives
which are as under.




SECTION-II : Synthesis  and biological  screening of  3- [4 ' -




SYNTHESIS AND BIOLOGICAL SCREENING OF 3-[4'-(ARYLIDENE)-
5'-OXO-2'-PHENYL-1'-IMIDAZOLYL]-2-[1"-(4'''-CHLOROPHENYL)-2"-
METHYL PROPYL]-QUINAZOLIN-4-(3H)-ONE.
5-Oxo imidazolinones one of the most active classes of compounds having
a wide spectrum of biological activities with an aim to getting better therapeutic
agent. The preparation of 5-oxo-imidazolines of Type-(X) have been undertaken
by the condensation of 3-amino-2-[1'-(4"-chlorophenyl)-2'-methyl propyl]-
quinazolin-4-(3H)-one with different oxazolones.
The constitution of the synthesised products have been characterised by
elemental analyses, IR, NMR and Mass spectral data.
The products were screened for their antimicrobial activity at a concentration











Type (X) R = Aryl
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IR SPECTRAL STUDY OF 3-[4'-(4""-CHLOROBENZYLIDENE)-5'-OXO-2'-PHENYL-1'-
IMIDAZOLYL]2-[1"-(4'''-CHLOROPHENYL)-2"-METHYLPROPYL]-QUINAZOLIN-4-(3H)-ONE.
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2960 2975–2950 110,111,112
–CH3 C – H str. (sym) 2869 2890–2850 "
C – H def. (asym) 1448 1470–1435 "
C – H def. (sym) 1361,1407 1385–1365 "
doublet iso propyl
=CH C – H (Alkene) 981 995–985 "
Aromatic C–H str. 3045 3080–3030 110,111, 112
C = C Ring Skeletal 1488,1510,1554 1600–1450 "
C–H o.o.p. def. 823 832–802 "
C–N str. 1299 1350–1200 "
Imidazolone C = O str. 1701 1720–1700 112
Moiety C = N str. 1652 1660–1630 "













NMR SPECTRAL STUDY OF 3-[4'-(4""-CHLORO BENZYLIDENE)-5'-OXO-2'-PHENYL-
1'-IMIDAZOLYL]2-[1"-(4"'-CHLOROPHENYL)-2"-METHYLPROPYL]-QUINAZOLIN-4-
(3H)-ONE.
Internal Standard : TMS; Solvent : DMSO   : Instrument : BRUKER Spectrometer (200 MHz)
Signal Signal Position Relative No. Multiplicity Inference
No. (δ ppm) of Protons
1 0.7 6H doublet –CH3a
2 1.04 1H multiplet –CHb
3 1.3 1H doublet –CHc
4 8.2–8.6 8H multiplet Ar–Hd
5 7.5–7.7 4H singlet Ar–He
6 7.2–7.4 5H singlet Ar–Hf


































































































































































































– – – – 2–NO2
.C6H4–(20)
– – – – 2–Cl.C6H4–(21)
– – – – 2,4–(Cl)2
.C6H3–(20)
Comparable activity with known standard drugs :-
Ampicillin 22 18 19 27 –
Chloramphenicol 24 19 25 26 –
Norfloxacin 24 19 25 26 –
Griseofulvin – – – – 23
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
Antimicrobial activity :-
Conclution




B. mega B. subtilis E. coli P. vulgaris A. niger











































PREPARATION OF 3- [4 ' - (ARYLIDENE)-5 ' -OXO-2 ' -PHENYL-1 ' -
IMIDAZOLYL]-2-[1"-(4' ' '-CHLOROPHENYL)-2"-METHYL PROPYL]-
QUINAZOLIN-4-(3H) ONE.
(A) Synthesis of 2-{[2'-(4"-Chlorophenyl)-3'-methyl butanoyl]amino}-
benzoic acid.
For see Part-II, Section-II, Page No. 90.
(B) Synthesis of 2-[1'-(4"-Chlorophenyl)-2'-methyl propyl]-3-amino
quinazolin-4-(3H) one.
For see Part-II, Section-II, Page No. 90.
(C) Synthesis of 3-[4'-(4""-Chloro benzylidene)-5'-oxo-2'-phenyl-1'-
imidazolyl]-2-[1"-(4'''-chlorophenyl)-2"-methyl propyl]-quinazolin-
4-(3H)-one.
A mixture of 2-[1'-(4"-chlorophenyl)-2'-methyl propyl]-3-amino quinazolin-
4-(3H)-one (3.27 g, 0.01 M) 4-(4'-chlorobenzylidine)-2-phenyl-5-oxazolone
(2.83 g, 0.01 M) in pyridine (10 ml) was refluxed for 4 hrs at 120oC. The isolated
product was dried and crystalised from ethanol, yield : 83.30% m.p.: 122oC,
(Found: C, 68.64; H, 4.33; N, 9.39; C34H26O2N4Cl2 required : C, 68.80; H,
4.38; N, 9.44%).
Similarly other imidazolinones were synthesised. The physical constants are
recorded in Table No. 19.
(D) Antimicrobial activity of 3-[4'-(Arylidene)-5'-oxo-2'-phenyl-1'-
imidazolyl]-2-[1"-(4'''-chlorophenyl)-2"-methyl propyl]-quinazolin-
4-(3H)-one.
The antimicrobial testing was carried out as described in Part-I, Section-I,
























1 C6H5– C34H27O2N4Cl 94 52.18 10.02 10.00
2 2–OH.C6H4– C34H27O3N4Cl 71 58.48 9.74 9.70
3 4–OH.C6H4– C34H27O3N4Cl 120 60.78 9.74 9.71
4 2–OCH3
.C6H4– C35H29O3N4Cl 91 62.68 9.51 9.48
5 3–OCH3
.C6H4– C35H29O3N4Cl 96 63.02 9.51 9.49
6 4–OCH3
.C6H4– C35H29O3N4Cl 65 60.99 9.51 9.50
7 2,4–(OCH3)2
.C6H3– C36H31O4N4Cl 94 68.72 9.05 9.00
8 3,4–(OCH3)2
.C6H3– C36H31O4N4Cl 98 63.36 9.05 9.03
9 2,5–(OCH3)2
.C6H3– C36H31O4N4Cl 90 63.09 9.05 9.02
10 3,4,5–(OCH3)3
.C6H2– C37H33O5N4Cl 80 57.88 8.63 8.60
11 3–OCH3,4–OH
.C6H3– C35H29O4N4Cl 52 61.58 9.26 9.21
12 3–C6H5
.OC6H4– C40H31O3N4Cl 81 53.82 8.60 8.58
13 2–NO2
.C6H4– C34H26O4N5Cl 198 63.72 11.59 11.57
14 3–NO2
.C6H4– C34H26O4N5Cl 122 67.16 11.59 11.55
15 2–Cl.C6H4– C34H26O2N4Cl2 98 62.76 9.44 9.40
16 4–Cl.C6H4 C34H26O2N4Cl2 122 83.30 9.44 9.39
17 2,4–(Cl)2
.C6H3– C34H25O2N4Cl3 60 65.36 8.92 8.88
18 2–Br.C6H4– C34H26O2N4ClBr 148 58.27 8.79 8.76
19 4–SCH3
.C6H4– C35H29O2N4SCl 72 59.42 9.26 9.22
20 2–OH, 3,5(Br)2
.C6H2– C34H25O3N4ClBr2 76 61.72 7.64 7.60
21 C4H3O C32H25O3N4Cl 155 62.63 10.20 10.18
22 C6H5–CH=CH– C36H29O2N4Cl 73 61.08 9.58 9.55
23 4–N,N–(CH3)2




TABLE NO. 20 : ANTIMICROBIAL ACTIVITY OF 3-[4'-(ARYLIDENE)-5'-OXO-2'-PHENYL-1'-IMIDAZOLYL]-2-[1"-
(4'''CHLOROPHENYL)-2"-METHYL PROPYL]QUINAZOLIN-4-(3H)-ONE.
1 C6H5– 15 13 21 18 23
2 2–OH.C6H4– 14 17 19 17 20
3 4–OH.C6H4– 15 14 16 15 21
4 2–OCH3
.C6H4– 13 16 23 16 20
5 3–OCH3
.C6H4– 15 14 18 14 19
6 4–OCH3
.C6H4– 16 15 15 15 21
7 2,4–(OCH3)2
.C6H3– 14 15 17 16 20
8 3,4–(OCH3)2
.C6H3– 13 17 18 18 19
9 2,5–(OCH3)2
.C6H3– 18 14 17 22 18
10 3,4,5–(OCH3)3
.C6H2– 11 16 16 18 17
11 3–OCH3,4–OH
.C6H3– 16 18 18 19 22
12 3–C6H5
.OC6H4– 15 18 19 17 18
13 2–NO2
.C6H4– 17 19 20 18 20
14 3–NO2
.C6H4– 19 18 18 21 17
15 2–Cl.C6H4– 18 19 18 19 21
16 4–Cl.C6H4 16 16 14 16 18
17 2,4–(Cl)2
.C6H3– 19 18 19 11 20
18 2–Br.C6H4– 18 15 21 17 19
19 4–SCH3
.C6H4– 11 15 11 21 16
20 2–OH, 3,5(Br)2
.C6H2– 13 14 14 15 16
21 C6H3O 12 13 16 17 15
22 C6H5–CH=CH– 15 12 17 12 16
23 4–N,N.(CH3)2–C6H4– 19 18 18 19 18
Sr. No. R B. mega B. subtilis E. coli P. vulgaris A. niger
1 2 3 4 5 6 7
Antibacterial activity
Zone of inhibition in m.m.
Antifungal activity





SYNTHESIS AND BIOLOGICAL SCREENING OF 3-[4'-(ARYLIDENE)-
5'-OXO-2'-PHENYL-1'-IMIDAZOLYL]-2-(PHENYL)-QUINAZOLIN-4-(3H)-
ONE.
5-Oxo imidazolines represent one of the most active classes of compounds
having a wide spectrum of biological activities with an aim to getting better
therapeutic agent. The synthesis of 5-oxo-imidazolines of type-(XI) have been
undertaken by the condensation of 3-amino-2-phenyl quinazolin-4-(3H)-one with
different oxazolones.
The constitution of the synthesised products have been characterised by
elemental analyses IR, NMR and Mass spectral data.
The products were screened for their antimicrobial activity at a concentration








R = ArylType (XI)
154
IR SPECTRAL STUDY OF 3-[4'-(2",5",DIMETHOXY BENZYLIDENE)-5'-OXO-2'-PHENYL-
1'-IMIDAZOLYL]-2-(PHENYL)-QUINAZOLIN-4-(3H)-ONE.
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2962 2975–2950 110,111,112
C – H str. (sym) 2871 2890–2860 "
C – H def. (asym) 1448 1470–1435 "
=CH C – H (Alkene) 981 995–985 "
Aromatic C–H str. 3065 3080–3030 111, 112
C = C str. Ring Skeletal 1488,1554 1600–1450 "
C–H o.o.p. def. 823 832–802 "
C–N str. 1299 1350–1200 "
Imidazolone C = O str. 1697 1760–1655 112
C = N str. 1587 1660–1630 "










NMR SPECTRAL STUDY OF 3-[4'-(2",5",DIMETHOXY BENZYLIDENE)-5'-OXO-2'-
PHENYL-1'-IMIDAZOLYL]-2-(PHENYL)-QUINAZOLIN-4-(3H)-ONE.
Internal Standard : TMS; Solvent : DMSO   : Instrument : BRUKER Spectrometer (200 MHz)
Signal Signal Position Relative No. Multiplicity Inference
No. (δ ppm) of Protons
1 3.5–3.7 6H singlet Ar–OCH3
2 8.5 1H singlet Ar–Ha
3 8.1 2H doublet Ar–Hb
4 3.89 1H singlet Ar–Hc
5 7.67 10H singlet Ar–Hd












































































































































.C6H3–(20) – – –
3–OCH3,4–OH
.C6H5–(21) 3–Br
.C6H4–(19) – – –
3–Br.C6H4–(20) – – – –
Comparable activity with known standard drugs :-
Ampicillin 22 18 19 27 –
Chloramphenicol 24 19 25 26 –
Norfloxacin 24 19 25 26 –
Griseofulvin – – – – 23
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
Antimicrobial activity :-
Conclution




B. mega B. subtilis E. coli P. vulgaris A. niger






























SYNTHESIS OF 3- [4 ' - (ARYLIDENE)-5 ' -OXO-2 ' -PHENYL-1 ' -
IMIDAZOLYL]-2-(PHENYL)-QUINAZOLIN-4-(3H)-ONE.
(A) Synthesis of 2-(Benzoyl amino)-benzoic acid.
A mixture of Anthranilic acid (1.37g, 0.01M) benzoyl chloride (1.44ml,
0.01M) and pyridine (5ml) refluxed at 1hrs at 120oC. The product was cooled
and poured onto crushed ice filtered and washed with cold water and dried. The
isolated product was crystallised from methanol. Yield : 86.59%, m.p.: 159oC
(Found : C, 69.68; H, 4.53; N, 5.76; C14H11O3N required C, 69.70; H, 4.56; N,
5.80%).
(B) Synthesis of 3-Amino-2-phenyl quinazolin-4-(3H) one.
A mixture of 2-(benzoyl amino) benzoic acid. (2.41 g, 0.01 M) hydrazine
hydrate (2 ml) and ethanol (25 ml) was refluxed for 3 hrs. The content was poured
on to crushed ice, filtered and wahsed with water. The isolated products was
crystilised from ethanol. Yield : 86.23%, m.p.: 139oC, (Found : C, 70.84; H, 4.60;
N,17.69 ; C14H11ON3 required : C, 70.88; H, 4.64; N,17.72%).
(C) Synthesis of 3-[4'-(2",5"-Dimethoxy benzylidene)-5"-oxo-2'-phenyl-
1'-imidazolyl]-2-(phenyl)-quinazolin-4-(3H)-one.
A mixture of 3-amino-2-phenyl-quinazolin-4-(3H)-one (2.37 g, 0.01 M),
4-(2',5'-dimethoxy benzylidine)-2-phenyl-5-oxazolone (3.09 g, 0.01 M), pyridine
(10 ml) was refluxed for 4 hrs at 120oC. The isolated product was dried and
crystallised from ethanol. Yield  : 78.92%, m.p.: 154oC, (Found : C, 75.11; H,
4.66; N, 10.91, C32H24O4N4 required : C,75.14; H, 4.69; N, 10.95%).
Similarly other imidazolones were synthesis. The physical constants are
recorded in Table No. 21.
(D) Antimicrobial activitiy of 3-[4'-(Arylidene-5'-oxo-2'-phenyl)-1'-
imidazolyl]-2-(phenyl)-quinazoline-4-(3H)-one
The antimicrobial testing was carried out as described in Part-I, Section-I,
























1 C6H5– C30H20O2N4 135 80.42 11.96 11.91
2 2–OH.C6H4– C30H20O3N4 128 71.82 11.57 11.52
3 3–OH.C6H4– C30H20O3N4 154 74.89 11.57 11.54
4 2–NO2
.C6H4– C30H19O4N5 148 58.65 13.64 13.60
5 3–NO2
.C6H4– C30H19O4N5 102 70.42 13.64 13.62
6 2–Cl.C6H4– C30H19O2N4Cl 173 84.40 11.14 11.08
7 4–Cl.C6H4– C30H19O2N4Cl 104 81.30 11.14 11.07
8 2,4–(Cl)2
.C6H3– C30H18O2N4Cl2 159 62.42 10.42 10.36
9 2–OCH3
.C6H4– C31H22O3N4 186 74.44 11.24 11.20
10 3–OCH3
.C6H4– C31H22O3N4 142 65.41 11.24 11.21
11 4–OCH3
.C6H4– C31H22O3N4 158 59.97 11.24 11.19
12 2,5–(OCH3)2
.C6H3– C32H24O4N4 154 78.42 10.60 10.55
13 3,4–(OCH3)2
.C6H3– C32H24O4N4 161 72.22 10.60 10.52
14 3–OCH3, 4–OH
.C6H3– C31H22O4N4 143 81.42 10.89 10.87
15 3–Br.C6H4– C30H19O2N4Br 132 78.72 10.23 10.20
16 C6H5–CH=CH– C32H22O2N4 108 64.42 11.33 11.31 16
2
TABLE NO. 22 : ANTIMICROBIAL ACTIVITY OF 3-[4 ' - (ARYLIDENE)-5 ' -OXO-2' -PHENYL-1 ' - IMIDAZOLYL]-2-
(PHENYL)-QUINAZOLIN-4-(3H)-ONE.
1 C6H5– 18 14 16 19 11
2 2–OH.C6H4– 20 17 18 22 16
3 3–OH.C6H4– 19 14 16 13 19
4 2–NO2
.C6H4– 12 21 18 14 20
5 2–NO2
.C6H4– 13 15 17 16 14
6 2–Cl.C6H4– 16 13 12 18 10
7 4–Cl.C6H4– 21 18 16 12 12
8 2,4–(Cl)2
.C6H3– 24 19 18 14 11
9 2–OCH3
.C6H4– 20 17 12 18 14
10 3–OCH3
.C6H4– 19 14 17 16 10
11 4–OCH3
.C6H4– 16 20 19 12 18
12 2,5–(OCH3)2
.C6H3– 18 16 20 19 17
13 3,4–(OCH3)2
.C6H3– 17 20 19 14 16
14 3–OCH3, 4–OH
.C6H3– 21 14 15 17 20
15 3–Br.C6H4– 20 19 17 15 12
16 C6H5–CH=CH– 18 16 14 12 18
Sr. No. R B. mega B. subtilis E. coli P. vulgaris A. niger
1 2 3 4 5 6 7
Antibacterial activity
Zone of inhibition in m.m.
Antifungal activity









The chemistry of chalcones (M) have generated intensive scientific studies
throughout the world specially interesting are their biological and industrial
applications. Chalcones are coloured compounds because of the presence of the
chromophore, auxochromes. They are known as benzalacetophenones or
benzylidene acetophenones. Kostanecki and Tambor363 gave the name
"Chalcone".
Chalcone are characterised by their possession of a structure in which two
aromatic rings A and B are linked by an aliphatic three carbon chain.
The alternative names given to chlalcones are phenyl styryl ketones,
benzalacetophenone, β-phenyl acrylphenone, γ-oxo-α-γ-diphenyl-α-propylene
and α-phenyl-β-benzoethylene.
SYNTHTIC ASPECT :
A considerable variety of methods are available for the synthesis of
chalcones. The most convenient method is one that involves the Claisen-Schmidt
condensation of equimolar quantities of an aryl methyl ketones with aryl
aldehyde in presence of alcoholic alkali.364
Several condensing agents used are alkali of different strength365,366





anhydrous Aluminium Chloride371, Boron trifluoride372, aqueous solution of
borax373, amino acid374 and perchloric acid375 etc.
MECHANISM :
Chalcone formation proceeds through aldol type of condensation and the
process is catalysed by the presence of alkali376. Following steps of the reaction
mechanism are as under.
The intermediate Aldol type of products formed readily undergoes
dehydration even under mild condition, particularly when R and R' are aryl
groups.
REACTIVITY OF CHALCONES :
The chalcone have been found to be useful for the synthesis of variety of
heterocyclic compounds are as under.
[a] Pyrazolines377 and its derivatives can be prepared by the condensation of
chalcones with hydrazine hydrate and acetic acid.
[b] Chalcones on condensation with malononitrile and ammonium acetate
yields 2-amino-3-cyano pyridines.378
(i) CH3COR    + OH–              –CH2COR + H2O



















[c] Isoxazoles379 can be prepared by the treatment of chalcones with
hydroxylamine hydrochloride and sodium acetate.
[d] Chalcone on condensation with malononitrile in pyridine forms 2-amino 3-
cyanopyrans.380
[e] Chalcones on treatment with urea in presence of alkali affords 2-oxo
pyrimidines.381
[f] Chalcones on reaction with thiourea in presence of alkali/acid yields 2-
thienopyrimidines.382
[g] Chalcones on treatment with guanidine hydrochloride in presence of alkali
affords 2-amino pyrimidines.383
[h] Chalcones reacts with P2S5 yielding 2-isothiazolines.
384
[i] Chalcones with sodium nitrile in presence of glacial acetic acid in ethanol
produces 2-1H-pyrimidines.385
[j] Chalcones with monoethanolamine in ethanol gives 1,4-oxazipines.386
[k] Chalcones wi th 2-amino thiophenol  in acet ic  acid produces 1,5-
thiazepines.387
[l] Chalcones on reaction with semicarbazide hydrochloride in ethanol affords
1-caroxamide pyrazolines.388
[m] Chalcones on reaction with 2-aminopyrimidine in glacial acetic acid affords
pyrido pyrimidines.389
[n] Oxiran390 can be prepared by the reaction of chalcone with H2O2 in basic
media.
[o] Cyanopyridone391 derivatives can be prepared by the condensation of
chalcone with ethalcyanoacetate.
[p] Chalcones gives imine derivatives with amine in presence of sulphuric acid
as a catalyst.392
[q] Chalcone on reaction with barbituric acid gave barbitone393 derivatives.
THERAPEUTIC INTEREST :
Chalcones are potential biocides, some naturally occuring antibiotics and
















Moreover, synthesis and antibacterial activity of substituted chalcone
derivatives have been reported by Modi et al.412 and A. Attia413, V. Mudalir et
al.414 have prepared phenoxy chalcones and observed their insecticidal acitvity.
Kammei et al.415 have synthesised phenoxychalcones and observed their
insecticidal activity. Kammeri et al.415 have synthesised chalcone derivatives
having antitumor activity. De vincenzo et al.416 and Han et al.417 have reported
chalcone derivatives for their antiinflammatory activity. Okuyana et al.418 have
been reported chalcone derivatives reductase inhibitor activity. Antitumor and
antifungal activity as reported by Tsotitus and co-worker419. Antifeedant activity
of chalcones have been observed by Sarma and Sreenivasulu.420
Ezio Bombardelli et al.421 have demonstrated that chalcone possess a
valuable antiproliferation activity both on sensitive cancereous cell and on cell
which are resistant to common chemotherapeutic drugs. Some of the chalcones
have been patented for their use for treatment of glaucoma422 and showed
ant i fungal423,424 a ldose reductase inhib i tor425,  ant icancer426 and
antimicrobial427,428 activites.
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Recently, Ni Liming et al.429 have synthesised chalcones and screened for
their antiinflammatory and cardiovascular activity. Kumar Srinivas et al.430 have
synthesised chalcones as a antitumor agent. Ko Horng Huey et al.431 have
prepared chalcones as antiinflammatory agent. Nakahara Kazuhiko et al.432 have
synthesised chalcones as carcinogen inhibitors. Antitubercular agents of chalcone
derivative have been prepared by Lin Yah meei et al.433
Das B. P. et al.434 have found that chalcones possesses larvicidal properties.
Kim Min Young et al.435 have synthesised chalcones and tested for their matrix
metalloproteinase inhibitor activity.
Liu Mei et. al.436 have prepared antimalarial chalcones. Opletalova veronika
et. al.437 have synthesised chalcones and screened as cardiovascular agent.
Moreover, it has been found that chalcone derivatives possesses nitric oxide
inhibitor438,439 anti-HIV440,441 and antiprotiferative442,443 activities.
Chalcone bearing a very good synthon, variety of novel heterocycles with
good pharmacological profile can be designed. These valid observation led us
to explore chalcone chemistry by synthesising several derivatives like isoxazoles,
pyrazolines, pyrimidine, bearing different heterocyclic ring systems for medicinal
value, in order to achieving better therapeutic agents, this study described as
under.





SYNTHESIS AND BIOLOGICAL SCREENING OF 3-{4'-[(3"-ARYL)-2"-
PROPENE-1"-ONE]-PHENYL}-2-(PHENYL) QUINAZOLIN-4-(3H)-ONE.
Recently much interest has been focoused on the synthesis and biodynamic
activities of chalcones and it is a good synthon for vaious heterocyclic rings. With
a view to obtained compounds having better therapeutic activity. 3-{4'-[(3''-aryl)-
2' '-propene-1''-one]-phenyl}-2-(phenyl) quinazolin-4-(3H)-one have been
synthesis by the condensation of 3-(4'-acetylphenyl)-2-(phenyl)-quinazolin 4-
(3H)-one with various aromatic aldehyde in presence of alkali. The latter was 3-
(4'-acetylphenyl)-2-(phenyl)-quinazolon 4-(3H) one have been synthesis 2-
(benzoyl amino) benzoic acid with 4-amino aceto phenone.
The constitution of the synthesised products have been characterised by
elemental analyses, IR, NMR and Mass spectral data.
The products were screened for antimicrobial activity at a concentration of






Type (XII) R = Aryl
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IR SPECTRAL STUDY OF 3-{4'-[3"-(2'"-METHOXYPHENYL)-2"-PROPENE-1"-ONE]-
PHENYL}-2-(PHENYL) QUINAZOLIN-4-(3H)-ONE.
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2929 2975–2950 110,111,113
C – H def. (asym) 1446 1470–1450 "
C – H def. (asym) 1375 1385–1370 "
Aromatic C–H str. 3050 3090–3030 113
C = C Ring Skeletal 1490,1515,1585 1600–1450 "
α,β- –C=O str. 1687 1685–1665 110
unsaturated
Ketone –CH=CH str. (vinylic) 1668 1644–1618 "
–C–H (vinylic) 991 995–975 "
Ether C–O–C str. 1161 1200–1100 109
Quinazolone C=O str. (Ketone) 1668 1690–1660 113
moiety. C=N str. 1585 1660–1630 "







NMR SPECTRAL STUDY OF 3-{4'-[3"-(2'"-METHOXYPHENYL)-2"-PROPENE-1"-ONE]-
PHENYL}-2-(PHENYL) QUINAZOLIN-4-(3H)-ONE.
Internal Standard : TMS; Solvent : DMSO   : Instrument : DPS-200 Spectrometer (200 MHz)
Signal Signal Position Relative No. Multiplicity Inference
No. (δ ppm) of Protons
1 3.30–3.32 3H singlet Ar–OCH3
2 6.9–7.2 4H multiplet Ar–Ha
3 4.9 1H doublet Hb (vinylic)
4 3.8 1H doublet Hc (vinylic)
5 7.9–8.0 2H doublet Ar–Hd
6 8.0–8.7 2H doublet Ar–He
7 7.60–7.65 5H singlet Ar–Hf









































































































– – 2–Cl.C6H4–(22) – 4–N, N–(CH3)2
.C6H4–(22)
Comparable activity with known standard drugs :-
Ampicillin 22 18 19 27 –
Chloramphenicol 24 19 25 26 –
Norfloxacin 24 19 25 26 –
Griseofulvin – – – – 23
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
Antimicrobial activity :-
Conclution




B. mega B. subtilis E. coli P. vulgaris A. niger






























(A) Synthesis of 2-(Benzoyl amino) benzoic acid.
For synthesis see Part-IV, Section-II, Page No. 161
(B) Synthesis of 3-(4'-Acetylphenyl)-2-(phenyl)quinazolin-4-(3H)-one.
A mixture of 2-(benzoylamino) benzoic acid (2.41 g, 0.01 M), 4-amino
acetophenone (1.35 g, 0.01 M) in ethanol (20 ml) was  refluxed on a oil bath at
120oC for 4 hrs. The content was cooled and poured onto crushed ice, filtered
and washed with water. The  isolated product was crystallised from ethaol. Yield:
83.24%; m.p.: 164oC, (Found : C: 77.60; H: 4.66; N: 8.19; C22H16O2N2
required : C: 77.64; H, 4.70; N: 8.23%).
(C) Synthesis of 3-{4'-[3"-(2"'-Methoxyphenyl)-2"-propene-1"-one]-
phenyl}-2-(phenyl) quinazoline-4-(3H)-one.
A mixture of 3-(4'-acetyl phenyl)-2-phenyl quinazolin-4-(3H)-one (3.40 g,
0.01 M) and 2-methoxy benzaldehyde (1.38 g, 0.01 M) in ethanol (25 ml), 40%
NaOH till the solution vigorously stirring at basic medium at 24 hrs. The contents
were poured into ice, acidified filtered and crystallized from ethanol. Yield :
92.98%, m.p.: 150oC. (Found : C: 78.51; H; 4.78; N: 6.08; C30H22O3N2
required : C : 78.60; H: 4.80; N: 6.11%).
Similarly other substituted chalcones have been synthesised. The physical
data are recorded in Table No. 23.
(D) Antimicrobial activity of 3-{4'-[(3"-Aryl)-2"-propene-1"-one]
phenyl}-2-(phenyl) quinazolin-4-(3H)-one.
The antimicrobial testing was carried out as described in Part-I, Section-I,
























1 C6H5– C29H20O2N2 158 69.82 6.54 6.51
2 2–OH.C6H4– C29H20O3N2 177 82.22 6.30 6.25
3 2–OCH3
.C6H4– C30H22O3N2 150 92.98 6.11 6.08
4 3–OCH3, 4–OH
.C6H3– C30H22O4N2 172 54.42 5.90 5.86
5 3,4–(OCH3)2
.C6H3– C31H24O4N2 98 92.24 5.73 5.70
6 2–NO2
.C6H4– C29H19O4N3 204 86.28 8.87 8.85
7 3–NO2
.C6H4– C29H19O4N3 148 70.84 8.87 8.83
8 2–Cl.C6H4– C29H19O2N2Cl 140 67.24 6.05 6.02
9 4–Cl.C6H4– C29H19O2N2Cl 172 90.08 6.05 6.03
10 4–N, N–(CH3)2




TABLE NO. 24 : ANTIMICROBIAL ACTIVITY OF 3-{4'-[(3"-ARYL)-2"-PROPENE-1"-ONE]-PHENYL}-2-(PHENYL)
QUINAZOLIN-4-(3H)-ONE.
1 C6H5– 16 12 23 17 22
2 2–OH.C6H4– 14 14 22 19 20
3 2–OCH3
.C6H4– 15 16 20 16 24
4 3–OCH3, 4–OH
.C6H3– 16 15 25 14 22
5 3,4–(OCH3)2
.C6H3– 13 13 20 13 18
6 2–NO2
.C6H4– 14 20 20 21 14
7 3–NO2
.C6H4– 18 17 18 15 15
8 2–Cl.C6H4– 17 12 22 17 16
9 4–Cl.C6H4– 15 14 16 21 20
10 4–N, N–(CH3)2
.C6H4– 17 22 16 21 22
Sr. No. R B. mega B. subtilis E. coli P. vulgaris A. niger
1 2 3 4 5 6 7
Antibacterial activity
Zone of inhibition in m.m.
Antifungal activity









Isoxazoles-(N) are a group of heterocyclic compounds containing two hetero
atoms : oxygen and nitrogen.
In 1888 claisen first suggest in isoxazoles (N) for a product from the reaction
of 1,3 diketone with hydroxylamine444 subsequently a solid foundation for the
chemistry of isoxazoles was laid down by claisen and his students. It was shown
to possess typical properties of an aromatic system but under certain reaction
conditions, particularly in reducing or basic media, it becomes very highly labile.
The next important contiribution to the chemistry of isoxazoles was made by
Quelico in 1946 when he began to study the formation of isoxazoles  from nitrile
N-oxides and unsaturated compounds.445
SYNTHETIC ASPECT :
Isoxazole may be prepared by the reaction between hydroxylamine and α,β−
unsaturated compounds the reaction proceeds via the formation of an oxime.
























Isoxazole can be prepared by various methods which are described as under.
Fanshawe and Crawly446 prepared isoxazole from chalcones hydroxylamine
hydrochloride and KOH in methanol.
THERAPEUTIC IMPORTANCE

















G. Daidone, Maggio et al.473 synthesised novel. 3-(isoxazol-3-yl)-
quinazol in-4-(3H)-one der ivat ives  and tes ted for  the i r  analges ic  and
antiinflammatory activities, as well as for their acute toxicity and ulcerogenic effect.
Some of them had a very low ulcerogenic effect.







R, R'  = aryl
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 C. B. Xue et al.474 reported the replacement of the benzamide in XUO57
(potent inhibitor) with an isoxazole carboxamide resulted in significant
improvement in vitro potency. More importanty the analogue XXUO65 showed
on excellent oral antiplatelet effect in dogs.
Masui et al.475 have prepared isoxazoles having pesticidal activity. some
excellent herbicidal results obtained by Reddy et al.476. Moreover isoxazoles
found to possess remarkable anxiolytic and antihypertensive effect, reported by
Nyitrai et al.477 Mishra et. al.478 have synthesised and reported isoxazoles as
useful agents for analgesic and antiinflammatory activities. Aicher et al.479 cited
some isoxazole derivatives possessing hypoglycemic agents.
Sezer Ozkan et al.480 have prepared 3-(1-phenyl-1,2,3-triazol-4-yl)
benziscreazoles (O) and studied their insecticidal acitvity.
M. Dauria481 studied photochemical behaviour of isoxazole derivatives.
Y. N. Manohara et al.482 investigated thermal decomposition kinetics of Co(II)
and Ni(II) complexes of substituted isoxazole and their antibacterial activity H.
Parekh and Akhil Bhatt483 have prepared isoxazole derivatives and documented
antitubercular activity. Some isoxazoles are found to possess herbicidal484-486
potential antiinflammatory487,488 and antimicrobial agents489,490 estrogen
receptor modulators491 and inhibitor of P38 MAP kinose activities.492
R. Ulrich et al.493 have synthesised isoxazole derivatives (P) and reported










When an intension of the compounds possessing better therapeutic activity,
we have undertaken the synthesised of isoxazoles bearing 4-(3H)-quinazolone
moiety which have been described as under.
















R1, R2 = H, halogen
R3 = H, halo, alkyl, alkoxy
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SECTION - I
SYNTHESIS AND BIOLOGICAL SCREENING OF 3-{4'-[(5"-ARYL)-
ISOXAZOLE-3"-YL]-PHENYL}-2-(PHENYL)-QUINAZOLIN-4-(3H)-ONE.
Taking into consideration of wide therapeutic activity of isoxazole derivatives.
The sythesis of 3-{4'-[(5"-aryl)-isoxazole-3"-yl]-phenyl}-2-(phenyl)-quinazolin-
4-(3H)-one have been synthesised by the condensation of 3-{4'-[(3"-aryl)-2"-
propene-1"-one]-phenyl}-2-(phenyl)-quinazolin-4-(3H)-one with hydroxyamine
hydrochloride.
The constituion of the products were supported by elemental analyses, IR,
NMR and Mass spectral data. The products were screened for antimicrobial activity








R = ArylType (XIII)
185
IR SPECTRAL STUDY OF 3-{4'-[(5"-(2'''-METHOXY PHENYL)-ISOXAZOLE-3"-YL]-
PEHNYL}-2-(PHENYL)-QUINAZOLIN-4-(3H)-ONE.
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2956 2975–2950 110,113
C – H str. (sym) 1463 1470–1435 "
C – H def. (asym) 1363 1390–1350 "
Aromatic C–H str. 3066 3090–3030 110,109
C = C Ring Skeletal 1512,1546 1600–1450 "
C–H o.o.p. def. 672,785,833 835–700 "
Quinazolone C=O str. (Ketone) 1651 1720–1700 113
moiety C – N str. 1244 1350–1200 "
C=N str. 1601 1660–1630 "







NMR SPECTRAL STUDY OF 3-{4'-[(5"-(2'''-METHOXY PHENYL)-ISOXAZOLE-3"-YL]-
PHENYL}-2-(PHENYL)-QUINAZOLIN-4-(3H)-ONE.
Internal Standard : TMS; Solvent : CDCl3   : Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference
No. (δ ppm) of Protons
1 3.71–3.83 3H singlet Ar–OCH3
2 6.92–6.99 4H multiplet Ar–Ha
3 6.95 1H doublet Ar–Hb
4 6.66 1H doublet Ar–Hc
5 7.18–7.22 2H doublet Ar–Hd
6 7.18–7.41 2H doublet Ar–He
7 7.60 5H singlet Ar–Hf














































































































Comparable activity with known standard drugs :-
Ampicillin 22 18 19 27 –
Chloramphenicol 24 19 25 26 –
Norfloxacin 24 19 25 26 –
Griseofulvin – – – – 23
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
Antimicrobial activity :-
Conclution




B. mega B. subtilis E. coli P. vulgaris A. niger




































(A) Synthesis of 2-(Benzoyl amino) benzoic acid.
Synthesis see Part-IV, Section-II, Page No. 161
(B) Synthesis of 3-[4'-Acetyl phenyl]-2-phenyl-quinazolin-4-(3H)-one.
Synthesis  see Part-V, Section-I, Page No. 177
(C) Synthesis of 3-{4'-[3"-(2'' '-Methoxyphenyl)-2'-propene-1"-one]-
phenyl}-2-(phenyl)-quinazolin-4-(3H)-one.
Synthesis see Part-V, Section-I, Page No. 177
(D) Synthesis of 3-{4'-[5"-(2' ' ' -Methoxy phenyl)-isoxazole-3"-yl]-
phenyl}-2-(phenyl)-quinazolin-4-(3H)-one.
A mixture of 3-{4'-[3"-(2'''-methoxy phenyl)-2'-propene-1"-one]-phenyl}-
2-(phenyl) quinazolin 4-(3H)-one (4.53 g, 0.01 M) hydroxyamine hydrochloride
(0.69 g, 0.01 M) and ethanol (20 ml). The reaction mixture was reflux at 120oC
for 5 hrs. The reaction mixture was cooled, poured into crushed. ice. filtered,
dried. The isolated product was crystallised from ethanol. Yield : 72.68%, m.p.:
142oC (Found C: 76.40; H: 4.40; N: 8.88, C30H21O3N3 required C, 76.43; H,
4.45; N, 8.91%)
Similarly other isoxazole were synthesised. The physical data are recorded
in Table No. 25.
(E) Antimicrobial activity of 3-{4'-[(5"-Aryl)-isoxazole-3"-yl]-phenyl}-
2-(phenyl)-quinazoline-4-(3H) one.
Antimicrobial testing was carried out as descreibed in Part-I, Section-I,
























1 C6H5– C29H19O2N3 138 68.62 9.52 4.49
2 2–OH.C6H4– C29H19O3N3 185 78.28 9.19 9.16
3 2–OCH3
.C6H4– C30H21O3N3 142 72.68 8.91 8.88
4 3–OCH3, 4–OH
.C6H3– C30H21O4N3 181 81.42 8.62 8.59
5 3,4–(OCH3)2
.C6H3– C31H23O4N3 121 74.42 8.38 8.32
6 2–NO2
.C6H4– C29H18O4N4 176 69.39 11.52 11.44
7 3–NO2
.C6H4– C29H18O4N4 174 66.82 11.52 11.48
8 2–Cl.C6H4– C29H18O2N3Cl 169 71.24 8.83 8.81
9 4–Cl.C6H4– C29H18O2N3Cl 98 78.49 8.83 8.80
10 4–N, N–(CH3)2




TABLE NO. 26 : ANTIMICROBIAL ACTIVITY OF 3-{4'-[(5"-ARYL)-ISOXAZOLE-3"-YL]-PHENYL}-2-(PHENYL)-
QUINAZOLINE-4-(3H)-ONE.
1 C6H5– 16 15 13 20 14
2 2–OH.C6H4– 18 12 14 18 19
3 2–OH3
.C6H4– 19 13 15 19 18
4 3–OCH3, 4–OH
.C6H3– 14 14 17 20 21
5 3,4–(OCH3)2–C6H3– 15 12 14 22 20
6 2–NO2
.C6H4– 18 14 16 20 19
7 3–NO2
.C6H4– 21 17 22 21 18
8 2–Cl.C6H4– 20 15 23 23 22
9 4–Cl.C6H4– 21 18 20 19 17
10 4–N, N–(CH3)2
.C6H4– 17 14 17 20 17
Sr. No. R B. mega B. subtilis E. coli P. vulgaris A. niger
1 2 3 4 5 6 7
Antibacterial activity
Zone of inhibition in m.m.
Antifungal activity









Amongst nitrogen containing five membered heterocycles, pyrazolines (Q)
have proved to be the most useful frame work for biological activities, pyrazolines
have attracted attention of medicinal chemistry for both with regard to heterocyclic
chemistry and the pharmacological activities associated with them in 1967 Jarobe,
reviewed the chemistry of pyrazolines, which have been studied extensively for
their biodynamic behaviour494 and industrial applications.495
SYNTHETIC ASPECT :
Different methods for the preparat ion of 2-pyrazol ine derivat ives
documented in literature are as follows.
(1) 2-pyrazolines can be constructed by the cyclocondensation of chalcones
with hydrazine hydrate.496
(2) 2-Pyrazoline can also be prepared by the condensation of chalcone
dibromide with hydrazines.497
(3) 2-Pyrazolines can be synthesised by the cycloaddition of diazomethane to
substituted chalcone.498
(4) Dipolar cycloaddition of nitrilimines of dimethyl fumarate fumaronitrile and














(5) Epoxidation of chalcones have epoxy ketones which reacted with hydrazine
and phenyl hydrazine to give pyrazolines.500
Furthermore, B. Gyassi et al.501 investigated the one pot synthesis of some
pyrazolines in dry media under microwave irradiation S. Paul et. al.502 and
Dandia Anshu et. al.503 have also described the microwave assited synthesis of
2-pyrazolines.
MECHANISM :
The following mechanism seems to be operable for the condensation of
chalcones with hydrazine hydrate.504
Nucleophilic attack by hydrazine at the β-carbon of the α,β-unsaturated
carbonyl system forms species (II) in which the-ve charge is mainly accomodated
by the electro nagative oxygen atom.
Proton transfer from the nitrogen to -ve oxygen produces an intermediate
enol which simultaniously ketonise to ketoamine (III). Another intramolecular
nucleophilic attack by the primary amino group of ketoamine on its carbonyl
carbon followed by proton transfer from nitrogen to oxygen leads ultimately to
carbonyl amine (IV). The later with a hydroxy group and amino group on the




























































S. S. Sonarc et al.525 have synthesised-3-(2-acetoxy-4-methoxy phenyl)-









Moreover, T. M. Stivenen et al.526 have also investigated N-substituted
pyrazoline type insecticides, Tanka Katsohori527 have patented pyrazoline
derivatives as herbicides and Johannes. et. al.528 as insecticides. Z. Moritiaz and
Hadol529 to investigated a semi emperial molecular orbital study on the reaction
of aminopyrazolinyl azodye with singlet molecular oxygen.
M. K. Shivnanda  and co-worker530 have prepared pyrazolines and reported
their antibacterial activity. B. Shivarama Holla et. al.531,532 have synthesised
pyrazolines as antibacterial agent. S. P. Hiremath et al.533 have synthesised
pyrazolines as analgesic, antiinflammatory and antimicrobial agent. V. Malhotra
et. al.534 have synthesised new pyrazolines as a cardiovascular agent.
Almstead et. al.535 have prepared pyrazolines as vascularization agent.
Guniz Kucukguzed et. al.536 have synthesised pyrazolines as a antimicrobial and
anticonvulsant agents.
 T. Z. Gulhan and co-workers537 have prepared pyrazolines as a hypotensive
agent. S. Sharma et. al.538 have synthesised pyrazolines and tested their
antiinflammatory activity. Ashok Kumar et. al.539 have synthesised pyrazolines
as anticonvulsant agent mayrer Fritz et al.540 have synthesised pyrazoles and
screened for their pesticidal activity.
In view of therapeutic activities shown by pyrazolines, it was contemplated
to synthesis some new pyrazolines in search of agent possessing higher biological
activitiy with least side effect have been described as under.
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SECTION-II : SYNTHESIS AND BIOLOGICAL SCREENING OF
3 -{4 ' - [5 " - (ARYL) -4 " ,5 " -D IHYDRO-1 " -ACETYL




SYNTHESIS AND BIOLOGICAL SCREENING OF 3-{4'-[(5"-ARYL)-
4",5"-DIHYDRO-1"-(H)-PYRAZOL-3"-YL]-PHENYL}-2-(PHENYL)-
QUINAZOLIN-4-(3H)-ONE.
Pyrazoline derivatives possess broad spectrum of pharmabiological activity
which are reflected by their use as analgesic, antiinflammatory, anticonvulsant,
antimicrobial and antipyretic agents. Prompted by above facts to synthesis 3-
{4'-[5"-(aryl)-4"-5"-dihydro-1"-(H)-pyrazol-3"-yl]-phenyl}-2-(phenyl)-quinazolin-
4-(3H) one of type (XIV) by the condensation between 3-{4'-[(3"-aryl)-2"-
propene-1"-one]-phenyl}-2-(phenyl) quinazolin-4(3H) one with hydrazine
hydrate.
The constitution of the products were supported by IR, NMR and Mass
spectral study. The products were screened for antimicrobial activity at a









R = ArylType (XIV)
IR SPECTRAL STUDY OF 3-{4'-[(5"-(2'''-METHOXY PHENYL)-4",5"-DIHYDRO-1"(H)-
PYRAZOL-3"-YL]-PHENYL}-2-(PHENYL)-QUINAZOLIN-4-(3H)-ONE.
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(sym.) 2954 2975–2950 110,113
C – H str. (asym) 1461 1470–1435 "
C – H def. (asym) 1361 1390–1350 "
Aromatic C–H str. 3045 3090–3030 109
C = C Ring Skeletal 1461,1514 1600–1450 "
C–H o.o.p. def. 727,823 835–700 "
Quinazolone C=O str. (Ketone) 1654 1720–1700 113
moiety C – N str. 1309 1350–1200 "
C=N str. 1654 1660–1630 "
Ether C–O–C str. 1150 1200–1100 109
Pyrazoline
ring N–H str. 3247 3320–3140 "







NMR SPECTRAL STUDY OF 3-{4'-[(5"-(2'''-METHOXY PHENYL)-4",5"-DIHYDRO-1"(H)-
PYRAZOL-3"-YL]-PHENYL}-2-(PHENYL)-QUINAZOLIN-4-(3H)-ONE.
Internal Standard : TMS; Solvent : DMSO   : Instrument : DPX-200 Spectrometer (200 MHz)
Signal Signal Position Relative No. Multiplicity Inference
No. (δ ppm) of Protons
1 3.7 3H singlet Ar–OCH3
2 7.04–7.2 4H multiplet Ar–Ha
3 2.3 1H triplet Hb
4 2.51 2H doublet Hc
5 7.0–7.18 2H doublet Ar–Hd
6 7.22–7.5 2H doublet Ar–He
7 7.7 5H singlet Ar–Hf
8 7.99–8.7 4H multiplet Ar–Hg


























































































































4–Cl.C6H4–(23) – 4–N, N–(CH3)2
.C6H4–(21) – –
Comparable activity with known standard drugs :-
Ampicillin 22 18 19 27 –
Chloramphenicol 24 19 25 26 –
Norfloxacin 24 19 25 26 –
Griseofulvin – – – – 23
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
Antimicrobial activity :-
Conclution




B. mega B. subtilis E. coli P. vulgaris A. niger

































SYNTHESIS AND BIOLOGICAL SCREENING OF 3-{4'-[(5"-ARYL)-
4",5"-DIHYDRO-1"-(H)-PYRAZOL-3"-YL]-PHENYL}-2-(PHENYL)-
QUINAZOLIN-4-(3H)-ONE.
(A) Synthesis of 2-(Benzoyl amino) benzoic acid.
For Synthesis see Part-IV, Section-II, Page No. 161
(B) Synthesis of 3-(4'-Acetyl phenyl)-2-(phenyl)-quinazolin-4-(3H)-one.
For Synthesis see Part-V, Section-I, Page No. 177
(C) Synthesis of 3-{4'-[3"-(2'''-methoxy phenyl)-2"-propene-1"-one]-
phenyl}-2-(phenyl)-quinazoline-4-(3H)-one.
For Synthesis see Part-V, Section-I, Page No. 177
(D) Synthesis of 3-{4'-[5"-(2'''-methoxy phenyl)-4",5"-dihydro-1"(H)-
pyrzol-3"yl]-phenyl}-2-(phenyl)-quinazolin-4-(3H)-one.
A mixture of 3-{4'-[3"-(2'''-methhoxy phenyl)-2"-propene-1"-one]-phenyl}-
2-(phenyl) quinazoline-4-(3H) one (4.58 g, 0.01 M) hydrazine hydrate (1.0 ml)
in methanol (15 ml) was refluxed for 12 hrs. The product was poured into crushed
ice filtered, washed with water and crystallised from dioxance. Yield : 69.43%;
m.p.: 159oC (found : C : 76.22; H: 5.04; N: 11.81; C30H24O2N4 required : C :
76.27; H : 5.08; N: 11.86%).
Similarly other pyrazolines were synthesised. The physical constants are
recorded in Table No. 27.
(E) Antimicrobial activity of 3-{4'-[5"-(aryl)4",5"-dihydro-1"-(H)-
pyrazol-3"-yl]-phenyl}-2-(phenyl)-quinazolin-4-(3H)-one.
The antimicrobial testing was carried out as described in Part-I, Section-I,
























1 C6H5– C29H22ON4 162 74.82 12.66 12.64
2 2–OH.C6H4– C29H22O2N4 156 79.48 12.22 12.20
3 2–OCH3
.C6H4– C30H24O2N4 159 69.43 11.86 11.81
4 3–OCH3, 4–OH
.C6H3– C30H24O3N4 158 72.41 11.47 11.42
5 3,4–(OCH3)2
.C6H3– C31H26O3N4 109 82.23 11.15 11.11
6 2–NO2
.C6H4– C29H21O3N5 162 76.24 14.37 14.32
7 3–NO2
.C6H4– C29H21O3N5 160 68.92 14.37 14.35
8 2–Cl.C6H4– C29H21ON4Cl 130 80.02 11.75 11.72
9 4–Cl.C6H4– C29H21ON4Cl 141 79.10 11.75 11.75
10 4–N, N–(CH3)2




TABLE NO. 28 : ANTIMICROBIAL ACTIVITY OF 3-{4'-[5"-(ARYL)-4",5"-DIHYDRO-1"-(H)-PYRAZOL-3"-YL]-PHENYL}-
2-(PHENYL)-QUINAZOLIN-4-(3H)-ONE.
1 C6H5– 16 14 13 15 17
2 2–OH.C6H4– 18 16 15 14 14
3 2–OCH3
.C6H4– 20 21 17 19 20
4 3–OCH3, 4–OH
.C6H3– 23 18 16 20 22
5 3,4–(OCH3)2
.C6H3– 21 17 21 24 21
6 2–NO2
.C6H4– 20 18 22 24 23
7 3–NO2
.C6H4– 18 18 20 19 18
8 2–Cl.C6H4– 20 22 23 24 23
9 4–Cl.C6H4– 23 17 21 20 16
10 4–N, N–(CH3)2
.C6H4– 17 15 21 17 19
Sr. No. R B. mega B. subtilis E. coli P. vulgaris A. niger
1 2 3 4 5 6 7
Antibacterial activity
Zone of inhibition in m.m.
Antifungal activity





SYNTHESIS AND BIOLOGICAL SCREENING OF 3-{4'-{5"-(ARYL)-4",
5"-DIHYDRO-1"-ACETYLPYRAZOL-3"-YL]-PHENYL}-2-(PHENYL)-
QUINAZOLIN-4-(3H)-ONE.
Acetyl pyrazoline derivatives procuring better therapeutic and antimicrobial
activities. Looking at their versatile therapeutic importance and with an aim  to
getting better drug, it was considered worthwhile to synthesise some new
pyrazoline. The synthesis of 3-{4'-[5"-(aryl)-4"-5"-dihydro-1"-acetyl pyrazol-3"-
yl]-phenyl}-2-(phenyl)-quinazolin-4-(3H)-one have been under taken by
cyclocondensation of chalcone of type (XII) with hydrazine hydrate and glacial
acetic acid.
The constitution of the products have been characterised by elemental
analyses, IR NMR and Mass spectral study. The products were screened for their









R = ArylType (XV)
211
IR SPECTRAL STUDY OF 3-{4'-[(5"-(2'''-METHOXY PHENYL)-4",5"-DIHYDRO-1"-N-
ACETYL-PYRAZOL-3"-YL]-PHENYL}-2-(PHENYL)-QUINAZOLIN-4-(3H)-ONE.
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(sym) 2964 2975–2950 110,113
C – H str. (asym) 1442 1470–1435 "
C – H def. (asym) 1358 1390–1350 "
Aromatic C–H str. 3040 3090–3030 109
C = C Ring Skeletal 1475,1514,1585 1600–1450 "
C–H o.o.p. def. 744,812 835–700 "
Quinazolone C=O str. 1691 1720–1700 113
moiety C – N str. 1263 1350–1200 "
C=N str. 1651 1660–1630 "
Ether C–O–C str. 1109 1200–1100 109









NMR SPECTRAL STUDY OF 3-{4'-[(5"-(2'''-METHOXY PHENYL)-4",5"-DIHYDRO-1"-N-
ACETYL-PYRAZOL-3"-YL]-PHENYL}-2-(PHENYL)-QUINAZOLIN-4-(3H)-ONE.
Internal Standard : TMS; Solvent : DMSO   : Instrument : BRUKER Spectrometer (200 MHz)
Signal Signal Position Relative No. Multiplicity Inference
No. (δ ppm) of Protons
1 3.76 3H singlet Ar–OCH3
2 7.04–7.60 4H multiplet Ar–Ha
3 1.23 1H triplet Hb
4 2.3 2H doublet Hc
5 7.04–7.22 2H doublet Ar–Hd
6 8.09 2H doublet Ar–He
7 7.70 5H singlet Ar–Hf
8 7.80–8.05 4H multiplet Ar–Hg







































































































































– – – 3–NO2
.C6H4–(22) 3–NO2
.C6H4–(23)
– – – 2–Cl.C6H4–(24) 4-Cl
.C6H4–(23)
– – – 4–Cl.C6H4–(24)
Comparable activity with known standard drugs :-
Ampicillin 22 18 19 27 –
Chloramphenicol 24 19 25 26 –
Norfloxacin 24 19 25 26 –
Griseofulvin – – – – 23
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity




B. mega B. subtilis E. coli P. vulgaris A. niger


































SYNTHESIS OF 3-{4 ' - [ (5" -ARYL)-4" ,5" -DIHYDRO-1" -ACETYL-
PYRAZOL-3"-YL]-PHENYL}-2-(PHENYL)-QUINAZOLIN-4-(3H)-ONE.
(A) Synthesis of 2-(Benzoyl amino) benzoic acid.
For Synthesis see Part-IV, Section-II, Page No. 161
(B) Synthesis of 3-(4'-Acetyl phenyl)-2-(phenyl)-quinazolin-4-(3H)-one.
For Synthesis see Part-V, Section-I, Page No. 177
(C) Synthesis of 3-{4'-[3"-(2'' '-Methoxy phenyl)-2"-propen-1"-one]-
phenyl}-2-(phenyl)-quinazoline-4-(3H)-one.
For Synthesis see Part-V, Section-I, Page No. 177
(D) Synthesis of 3-{4'-[5"-(2'' '-Methoxy phenyl)-4",5"-dihydro-1"-N-
acetyl-pyrazol-3"-yl]-phenyl}-2-(phenyl)-quinazolin-4-(3H)-one.
A mixture of 3-{4'-[3"-(2'''-methoxy phenyl)-2"-propen-1"-one]-phenyl}-2-
(phenyl)-quinazoline-4-(3H)-one (4.58 g, 0.01 M) hydrazine hydrate (1.0 ml)
glacetic acid (2.0 ml) and methanol (20 ml) was refluxed for 12 hrs The reaction
mixture is poured into crushed ice, filtered, washed with hot water and crystallised
from dioxane. Yield: 78.69%, m.p.: 155oC. (Found : C : 74.64; H : 5.00; N :
10.86; C32H26O3N4 required : C  74.70; H : 5.05; N : 10.89%).
Similarly others acetyl pyrazolines have been synthesised. The physical data
are recorded in Table No. 29.
(E) Antimicrobial activity of 3-{4'-[5"-Aryl]-4",5"-dihydro-1"-acetyl
pyrazol-3"-yl]-phenyl}-2-(phenyl)-quinazolin-4(3H)-one.
The antimicrobial testing was carried out as described in Part-I, Section-I,
























1 C6H5– C31H24O2N4 136 84.42 11.57 11.54
2 2–OH.C6H4– C31H24O3N4 140 68.92 11.20 11.16
3 2–OCH3
.C6H4– C32H26O3N4 155 78.69 10.89 10.86
4 3–OCH3, 4–OH
.C6H3– C32H26O4N4 102 76.43 10.56 10.52
5 3,4–(OCH3)2
.C6H3– C33H28O4N4 280(d) 69.84 10.29 10.22
6 2–NO2
.C6H4– C31H23O4N5 141 71.42 13.23 13.21
7 3–NO2
.C6H4– C31H23O4N5 130 69.90 13.23 13.20
8 2–Cl.C6H4– C31H23O2N4Cl 132 70.42 10.80 10.78
9 4–Cl.C6H4– C31H23O2N4Cl 138 74.98 10.80 10.77
10 4–N, N–(CH3)2




TABLE NO. 30 : ANTIMICROBIAL ACTIVITY OF 3-(4'-[5"-(ARYL)-4",5"-DIHYDRO-1"-ACETYL PYRAZOL-3"-YL]-
PHENYL}-2-(PHENYL)-QUINAZOLIN-4-(3H)-ONE.
1 C6H5– 16 14 14 16 16
2 2–OH.C6H4– 17 19 16 18 20
3 2–OCH3
.C6H4– 18 14 15 16 21
4 3–OCH3, 4–OH
.C6H3– 17 16 14 20 22
5 3,4–(OCH3)2–C6H3– 22 19 19 23 18
6 2–NO2
.C6H4– 18 15 16 21 22
7 3–NO2
.C6H4– 20 13 14 22 24
8 2–Cl.C6H4– 19 14 15 21 20
9 4–Cl.C6H4– 22 18 19 24 23
10 4–N,N–(CH3)2
.C6H4– 14 15 16 19 20
Sr. No. R B. mega B. subtilis E. coli P. vulgaris A. niger
1 2 3 4 5 6 7
Antibacterial activity
Zone of inhibition in m.m.
Antifungal activity








STUDIES ON PYRIMIDINE DERIVATIVES
INTRODUCTION
Pyrimidine derivatives occur in natural products541 like nucleic acid and
vitamin-B have remarkable pharmaceutical importance because of thier biological
activities542-545 several analogs of nucleic acids have been used as compound
that interfere with the synthesis and functioning of nucleic acids, and example is
fluorouracil which has been used in cancer treatment. Pyrimidines are among
those molecules that  make life possible as being same of the building blocks of
DNA and RNA.
Some pyrimidines of physiologically as well as pharmacologically importance
are as under : e.g. cytosine, beclmethrin(S), blasticidin (T).
Synthetic pyrimidine derivatives contribute much to the searchable literature
of pyrimidine derivtives, in huge libraries owing to their wide applicability in
different fields.
SYNTHETIC ASPECT :
Different methods for the synthesis of pyrimidine have been cited in the
literature.546





















The reaction of α,β-unsaturated system with urea leds to the formation of








































































Pyrimidine derivatives have proven to be of great importance in exhibiting
and enhancing the biological activities such as.
(a) Antitumor548
(b) Carcinostatic549










Moreover, Azaryan et al.572 have synthesised pyrimidine diones as antitumor
agent. Krivongov and co-worker573 have synthesised pyrimidinone derivatives
possessing immunotropic and antiinflammatory activitiy. M. T. Omer and co-
worker574 have prepared some new pyrimidine derivatives showed moderate
activity against the growth of Bacillus substilis, Staphylococus aureus and
Aspergillus niger. Amuti Kofies et. al.575 have suggested that pyrimidinone
















R1 = Alkyl, R2 = H, Halogen
224
K. Mogilaiah576 have prepared spiropyrimidinones as antibacterial. Drewes
and wilhelm577 have synthesised pyrimidinones as herbicidal agents.
Timothy and co-worker578 have suggested imidazolyl pyrimidinones as
antiviral Nagamatsu et. al.579 have prepared some new triazolo [3,4-c] pyrimidine
as xanthin oxidase inhibitors. A. Roland et. al.580 have prepared oxazolyl uracil
as herbicidal and insecticidal. M. M. Yari and co-worker581 have investigated
the pyrimidinone derivatives which possess calcium antagonist activity.
M. A. Bruce and co-worker582 prepared The dihydropyrimidinones as NPY
antagonist.


















Mona Mahram and co-worker584 have synthesied pyrimidine derivatives
as potent antimicrobial and antitumor agents.
A.  K.  Saxena and co-worker585 have prepared 2,6-disubst i tuted
pyrimidinones as CNS agent.
Pyrimidinone derivatives586,587 have found to be calcium channel blocker
M. M. Barbuliene et. al.588 have synthesised pyrimidinones as antiinflammatory
agent.
Recently, Amjad Ali et. al.589 have synthesised new fused pyrimidinones
as antimicrobial agents. Abd El-Galil et. al.590 have synthesised pyrimidine as
androgenic anabolic and antiinflammatory agents. martin Bolli et. al.591 have
synthesised pyrimidines as endothelin receptor antagonists. F. F. Patricia et. al.592
have synthesised and screened for their leukocyte functions inhibitor activity.
Dumas Jacques et al.593 have synthesised pyrimidines and tested their
hyderproliferative disorder activity. Adenosine receptor antagonist pyrimidinones





















In view of procuring better therapeutic agents to synthesis different types of
pyrimidine derivatives are as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL SCREENING OF
3-{4'-[6"-(ARYL)-2"-MERCAPTO-3",4"-DIHYDRO
P Y R I M I D I N - 4 " -Y L ] P H E N Y L - 2 - ( P H E N Y L )
QUINAZOLIN}-4-(3H)-ONE.
SECTION-II : SYNTHESIS AND BIOLOGICAL SCREENING OF
3-{4 ' - [6" - (ARYL)-2" -HYDROXY-3",4" -DIHYDRO




SYNTHESIS AND BIOLOGICAL SCREENING OF 3-{4'-[(6"-ARYL)-2"-
MERCAPTO-3",4"-DIHYDRO PYRIMIDIN-4"-YL]-PHENYL-2-(PHENYL)-
QUINAZOLIN-4-(3H)-ONE.
Looking to the interesting pharmacological and agricultural activity of
pyrimidine ring system. It was considered worthwhile to synthesis compounds
bearing quinazolin 4-(3H)-one nucles linked to the pyrimidinone nucleus.
Pyrimidinone of type (XVI) have been prepared by the condensation of 3-{4'-
[3"-aryl-2"-propene-1"-one]-phenyl}-2-(phenyl)-quinazoline-4-(3H)-one of type
(XII) with thiourea in presence of catalytic amount of alcoholic pottasium
hydroxide.
The constitution of the products were supported by elemental analyses, IR,
NMR, Mass spectral study. The products were screened for antimicrobial activity










R = ArylType (XVI)
228
IR SPECTRAL STUDY OF 3-{4'-[(6"-(2'''-METHOXY PHENYL)-2"MERCAPTO-3",4"-
DIHYDRO-PYRIMIDIN-4"-YL]-PHENYL-2-(PHENYL)-QUINAZOLIN-4-(3H)-ONE.
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(sym) 2962 2975–2950 110,113
C – H str. (asym) 1433 1470–1435 "
C – H def. (asym) 1380 1390–1350 "
Aromatic C–H str. 1390 3090–3030 109
C = C Ring Skeletal 1504,1585 1600–1450 "
C–H o.o.p. def. 758,821 835–700 "
Quinazolone C=O str. (Ketone) 1658 1720–1700 113
moiety C – N str. 1232 1350–1200 "
C=N str. 1585 1660–1630 "
Ether C–O–C str. 1161 1200–1100 109











NMR SPECTRAL STUDY OF 3-{4'-[(6"-(2'''-METHOXY PHENYL)-2"-MERCAPTO-3",4"-
DIHYDRO PYRIMIDIN-4"-YL]-PHENYL}-2-(PHENYL)-QUINAZOLIN-4-(3H)-ONE.
Internal Standard : TMS; Solvent : CDCl3   : Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference
No. (δ ppm) of Protons
1 3.8–3.9 3H singlet Ar–OCH3
2 7.02–7.26 4H multiplet Ar–Ha
3 1.22 1H triplet Hb
4 2.51 2H doublet Hc
5 7.02–7.22 2H doublet Ar–Hd
6 8.09 2H doublet Ar–He
7 7.63 5H singlet Ar–Hf
/8 7.80–8.09 4H multiplet Ar–Hg























































































































– – 4–Cl.C6H4–(22) – –
Comparable activity with known standard drugs :-
Ampicillin 22 18 19 27 –
Chloramphenicol 24 19 25 26 –
Norfloxacin 24 19 25 26 –
Griseofulvin – – – – 23
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity




B. mega B. subtilis E. coli P. vulgaris A. niger




































(A) Synthesis of 2-(Benzoyl amino) benzoic acid.
For Synthesis see Part-IV, Section-II, Page No. 161
(B) Synthesis of 3-[4'-Aceteyl phenyl]-2-(phenyl)-quinazolin-4(3H)-one.
For Synthesis see Part-V, Section-I, Page No. 177
(C) Synthesis of 3-{4'-[3"-(2"'-Methoxy phenyl)-2"-propene-1"-one]-
phenyl}-2-(phenyl)-quinazolin-4-(3H)-one.
For Synthesis see Part-V, Section-I, Page No. 177
(D) Synthesis of 3-{4'-[6"-(2"'-Methoxy phenyl)-2"-mercapto-3",4"-
dihydro pyrimidine-4"-yl]-phenyl-2-(phenyl)quinazolin-4-(3H)-one.
A mixture of 3-{4'-[3"-(2"'-methoxy phenyl)-2"-propene-1"-one]-phenyl}-
2-(phenyl) quinazolin-4(3H)-one (4.58 g, 0.01 M) and thiourea (0.66 g, 0.01 M)
was reluxed at 90oC for 14 hrs in presence of basic catathyst like alcoholic KOH
in methanol. The reaction mixture was poured into crushed ice filtered and dried.
The product was isolated, crystalized from dioxane. Yield: 68.71% m.p.: 164oC,
(Found : C : 72.20; H : 4.63; N : 10.84; C31H23O2N4S, C : 72.23 ; H : 4.66 ; N
: 10.87%).
Similarly other pyrimidines were synthesised. The physical constants are
recorded in Table No. 31.
(E) Antimicrobial activity of 3-{4'-[6"-(Aryl)-2"-mercapto-3"-4"-dihydro
pyrimidine-4"-yl]-phenyl-2-(phenyl)quinazolin-4-(3H)one.
Antimicrobial testing was carried out as described in Part-I, Section-I,
























1 C6H5– C30H21ON4S 160 74.52 11.54 11.51
2 2–OH.C6H4– C30H21O2N4S 166 62.42 11.17 11.12
3 2–OCH3
.C6H4– C31H23O2N4S 164 68.71 10.87 10.83
4 3–OCH3, 4–OH
.C6H3– C31H23O3N4S 156 70.12 10.54 10.50
5 3,4–(OCH3)2
.C6H3– C32H25O3N4S 137 78.44 10.27 10.22
6 2–NO2
.C6H4– C30H20O3N5S 178 72.49 13.20 13.16
7 4–NO2
.C6H4– C30H20O3N5S 170 58.79 13.20 13.17
8 2–Cl.C6H4– C30H20ON4SCl 173 84.23 10.78 10.72
9 4–Cl.C6H4– C30H20ON4SCl 169 81.42 10.78 10.75
10 4–N, N–(CH3)2




TABLE NO. 32 : ANTIMICROBIAL ACTIVITY OF 3-{4'-[6"-(ARYL)-2"-MERCAPTO-3",4"-DIHYDRO PYRIMIDIN-4"-YL]
PHENYL-2-(PHENYL)-QUINAZOLIN-4-(3H)-ONE.
1 C6H5– 12 14 15 14 16
2 2–OH.C6H4– 23 18 17 15 14
3 2–OCH3
.C6H4– 14 13 21 16 15
4 3–OCH3, 4–OH
.C6H3– 16 12 24 17 17
5 3,4–(OCH3)2
.C6H3– 24 17 23 16 16
6 2–NO2
.C6H4– 12 18 20 16 21
7 4–NO2
.C6H4– 13 17 20 13 18
8 2–Cl.C6H4– 22 20 19 20 17
9 4–Cl.C6H4– 14 12 22 15 16
10 4–N, N–(CH3)2
.C6H4– 17 22 16 21 24
Sr. No. R B. mega B. subtilis E. coli P. vulgaris A. niger
1 2 3 4 5 6 7
Antibacterial activity
Zone of inhibition in m.m.
Antifungal activity





SYNTHESIS AND BIOLOGICAL SCREENING OF 3-{4'-[(6"-ARYL)-2"-
HYDROXY-3",4"-DIHYDRO PYRIMIDIN-4"-YL]-PHENYL-2-(PHENYL)-
QUINAZOLIN-4 (3H)-ONE.
Looking to the interesting pharmacological and agricultural activity of
pyrimidine ring system. It was considered worthwhile to synthesis compounds
bearing quinazolin 4-(3H)-one nucleus linked to the pyrimidinone nucleus.
Pyrimidinone of type (XVII) have been synthesised by the condensation of 3-
{4'-[3"-aryl-2"-propene-1"-one]-phenyl}-2-(phenyl)-quinazoline-4-(3H)-one of
type (XII) with urea in presence of catalytic amount  of conc. HCl.
The constitution of the products were delineated by elemental analyses, IR,
NMR, Mass spectral study. The products were screened for antimicrobial activity










R = ArylType (XVII)
238
IR SPECTRAL STUDY OF 3-{4'-[(6"-(2'''-METHOXY PHENYL)-2"-HYDROXY-3",4"-
DIHYDRO PYRIMIDIN-4"-YL]-PHENYL}-2-(PHENYL)-QUINAZOLIN-4-(3H)-ONE.
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(sym.) 2962 2975–2950 110,113
C – H str. (asym) 1446 1470–1435 "
C – H def. (asym) 1388 1390–1350 "
Aromatic C–H str. 3060 3090–3030 109
C = C Ring Skeletal 1490,1523 1600–1450 "
C–H o.o.p. def. 756,819 835–700 "
N – H str. (asym) 3345 3550–3350 "
N – H def. 1585 1650–1550 "
Quinazolone C=O str. 1691 1720–1700 113
moiety C – N str. 1299 1350–1200 "
C=N str. 1606 1660–1630 "
Ether C–O–C str. 1091 1200–1100 109











NMR SPECTRAL STUDY OF 3-{4'-[(6"-(2'''-METHOXY PHENYL)-2"-HYDROXY-3",4"-
DIHYDRO-PYRIMIDIN-4"-YL]-PHENYL-2-(PHENYL)-QUINAZOLIN-4-(3H)-ONE.
Internal Standard : TMS; Solvent : DMSO   : Instrument : DPX-200 Spectrometer (200 MHz)
Signal Signal Position Relative No. Multiplicity Inference
No. (δ ppm) of Protons
1 3.82 3H singlet Ar–OCH3
2 7.02–7.26 4H multiplet Ar–Ha
3 1.23 1H triplet Hb
4 2.51 2H doublet Hc
5 7.02–7.22 2H doublet Ar–Hd
6 8.09 2H doublet Ar–He
7 7.68 5H singlet Ar–Hf
8 7.80–8.09 4H multiplet Ar–Hg














































































































– – 4–Cl.C6H4–(20) – –
– – – –
Comparable activity with known standard drugs :-
Ampicillin 22 18 19 27 –
Chloramphenicol 24 19 25 26 –
Norfloxacin 24 19 25 26 –
Griseofulvin – – – – 23
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
Antimicrobial activity :-
Conclution




B. mega B. subtilis E. coli P. vulgaris A. niger


































SYNTHESIS OF 3-{4' - [6"-(ARYL)-2"-HYDROXY-3",4"-DIHYDRO
PYRIMIDINE-4"-YL]-PHENYL-2-(PHENYL)-QUINAZOLIN-4(3H)-ONE.
(A) Synthesis of 2-(Benzoyl amino) benzoic acid.
For Synthesis see Part-IV, Section-II, Page No. 161
(B) Synthesis of 3-[4'-Aceteyl phenyl]-2-(phenyl)-quinazolin-4(3H)-one.
For Synthesis see Part-V, Section-I, Page No. 177
(C) Synthesis of 3-{4'-[3"-(2"'-Methoxy phenyl)-2"-propene-1"-one]-
phenyl}-2-(phenyl)-quinazolin-4-(3H)-one.
For Synthesis see Part-V, Section-I, Page No. 177
(D) Synthesis of 3-{4'-[6"-(2"'-Methoxy phenyl)-2"-hydroxy-3",4"-
dihydro pyrimidin-4"-yl]phenyl-2-(phenyl)quinazolin-4-(3H)-one.
A mixture of 3-{4'-[3"-(2"'-methoxy phenyl)-2"-propene-1"-one]-phenyl}-
2-(phenyl) quinazolin-4(3H)-one (4.58 g, 0.01M) and urea (0.60 g, 0.01 M) was
refluxed at 90o C for 14 hrs. in presence of acid catalyst like HCl in methanol.
The reaction product was poured into crushed ice. The product was isolated
crystallized from dioxane, Yield : 78.49%. m.p.: 165oC (Found : C, 74.51; H,
4.76; N, 11.20%). C31H24O3N4, required: C, 74.54; H, 4.80; N, 11.22%).
Similarly other pyrimidines were synthesised. The physical constant are
recorded in Table No. 33.
(E) Antimicrobial activity of 3-{4'-[6"-(Aryl)-2"-hydroxy-3"-4"-hydro
pyrimidine-4"-yl]-phenyl-2-(phenyl)quinazolin-4-(3H)-one.
Antimicrobial testing was carried out as described in Part-I, Section-I, Page
























1 C6H5– C30H21O2N4 146 69.44 11.94 11.91
2 2–OH.C6H4– C30H21O3N4 149 70.66 11.54 11.51
3 2–OCH3
.C6H4– C31H23O3N4 165 78.49 11.22 11.20
4 3–OCH3, 4–OH
.C6H3– C31H23O4N4 151 74.82 10.87 10.81
5 3,4–(OCH3)2
.C6H3– C32H25O4N4 198 68.96 10.58 10.52
6 2–NO2
.C6H4– C30H20O4N5 171 78.82 13.61 13.57
7 4–NO2
.C6H4– C30H20O4N5 120 82.48 13.61 13.58
8 2–Cl.C6H4– C30H20O2N4Cl 156 73.92 11.21 11.10
9 4–Cl.C6H4– C30H20O2N4Cl 142 76.31 11.21 11.11
10 4–N, N–(CH3)2




TABLE NO. 34 : ANTIMICROBIAL ACTIVITY OF 3-{4'-[6"-(ARYL)-2"-HYDROXY-3",4"-DIHYDRO PYRIMIDIN-4"-YL]
PHENYL-2-(PHENYL)-QUINAZOLIN-4-(3H)-ONE.
1 C6H5– 14 16 17 16 18
2 2–OH.C6H4– 21 20 19 17 16
3 2–OCH3
.C6H4– 16 15 19 18 17
4 3–OCH3, 4–OH
.C6H3– 18 14 22 19 19
5 3,4–(OCH3)2
.C6H3– 22 19 21 18 18
6 2–NO2
.C6H4– 14 20 18 15 20
7 4–NO2
.C6H4– 15 19 20 16 18
8 2–Cl.C6H4– 14 22 21 20 19
9 4–Cl.C6H4– 16 14 20 17 18
10 4–N, N–(CH3)2
.C6H4– 19 20 18 16 22
Sr. No. R B. mega B. subtilis E. coli P. vulgaris A. niger
1 2 3 4 5 6 7
Antibacterial activity
Zone of inhibition in m.m.
Antifungal activity
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